Список трудов авторов, использованных при подготовке статей по раку молочной железы (РМЖ) на сайте МедикалПланет

В статьях данного раздела сайта использованы следующие сокращения:

  • АДФ — аденозиндифосфат
  • АИХ — аменорея, индуцированная химиотерапией
  • ГнРГ — гонадотропин-рилизинг гормон
  • ГР — гомологичная рекомбинация
  • ДИ — доверительный интервал
  • ДНК — дезоксирибонуклеиновая кислота
  • ЗС — замороженный срез
  • ИА — ингибиторы ароматазы
  • ИГХ — иммуногистохимия
  • ИМТ — индекс массы тела
  • иРМЖ — ипсилатеральный рак молочной железы
  • кРМЖ — контралатеральный рак молочной железы
  • КСЯ — контролируемая стимуляция яичников
  • КТ — компьютерная томография
  • ЛУ — лимфатический узел
  • мРНК — матричная рибонуклеиновая кислота
  • МРПН — межреберно-плечевой нерв
  • МРР — местно-регионарный рецидив
  • МРТ — магнитно-резонансная томография
  • НАХТ — неоадъювантная химиотерапия
  • ОР — относительный риск
  • ОПЗ — отрицательное прогностическое значение
  • ОСО — органосохраняющая операция
  • ПЛ — подмышечная лимфаденэктомия
  • ПК — протоковая карцинома
  • ПМЛТ — постмастэктомическая лучевая терапия
  • ПНЯ — преждевременная недостаточность яичников
  • пПО — полный патоморфологический ответ
  • ППЗ — положительное прогностическое значение
  • ПФЯ — подавление функций яичников
  • ПЭТ — позитронно-эмиссионная томография
  • ПЭТ-КТ — позитронно-эмиссионная томография в сочетании с компьютерной томографией
  • РИ — радиоизотоп
  • РМЖ — рак молочной железы
  • РНК — рибонуклеиновая кислота
  • СЛУ — сигнальный лимфатический узел
  • ТИАБ — тонкоигольная аспирационная биопсия
  • ТИАЦ — тонкоигольная аспирационная цитология
  • тнРМЖ — тройной негативный рак молочной железы
  • УЗ-ТИАБ — тонкоигольная аспирационная биопсия под ультразвуковым контролем
  • УЗИ — ультразвуковое исследование
  • УЗИ с КУ — ультразвуковое исследование с контрастным усилением (contrast-enhanced ultrasound)
  • ЭТ — эндокринная терапия
  • ADM (от англ, acellular dermal matrix) — бесклеточная кожная матрица
  • ASCO — Американское общество клинической онкологии (American Society of Clinical Oncology)
  • BD — синий краситель (blue dye)
  • BI-RADS — шкала оценки результатов исследований молочной железы, разработанная Американской коллегией радиологов (Breast Imaging-Reporting and Data System)
  • DFS — выживаемость без признаков заболевания (disease-free survival)
  • DRFI (от англ, distant recurrence-free interval) — выживаемость без отдаленных рецидивов
  • EORTC (от англ. European Organization for Research and Treatment of Cancer) — Европейская организация по исследованию и лечению рака
  • ER (от англ, estrogen receptor) — рецептор эстрогена
  • ESMO (от англ. European Society for Medical Oncology) — Европейское общество медицинской онкологии
  • FN — тонкая игла/тонкоигольный (Fine Needle)
  • FNR — относительное число ложноотрицательных заключений (false-negative rate)
  • H&E — окраска гематоксилином и эозином (hematoxylin and eosin staining)
  • HER (от англ, human epidermal growth factor receptor) — рецептор эпидермального фактора роста
  • IBCSG (от англ. International Breast Cancer Study Group) - Международная группа по изучению рака молочной железы
  • ICG — индоцианиновый зеленый/индоцианин зеленый (indocyanine green)
  • IR — процент выявления (identification rate)
  • ITC — изолированное скопление опухолевых клеток (isolated tumour cell cluster)
  • LAS — взятие биопсии из нижней части подмышечной впадины (low axillary sampling)
  • LD (от лат. latissimus dorsi) — широчайшая мышца спины
  • MBD — метиленовый синий краситель (methylene blue dye)
  • NCCN (от англ. National Comprehensive Cancer Network) — Национальная комплексная онкологическая сеть
  • NICE — Национальный институт охраны здоровья и совершенствования медицинской помощи Великобритании (National Institute for Health and Clinical Excellence)
  • OSNA — одноэтапная амплификация нуклеиновых кислот (one step nucleic acid amplification)
  • РАМ50 (от англ, prediction analysis of the microarrays) — количественный анализ 50 генов с помощью полимеразной цепной реакции в режиме реального времени
  • PARP (от англ. poly-(ADP-ribose) polymerases) — поли-(АДФ-рибоза)-полимераза
  • pCR — полный патоморфологический ответ (pathological complete response)
  • PgR (от англ, progesterone receptor) — рецептор прогестерона
  • PI3K (от англ, phosphoinositide 3-kinase) — фосфоинозитид-3-киназа
  • ROR-PT (от англ, risk of recurrence score) — балл риска рецидива
  • SEER (от англ. Surveillance, Epidemiology, and End Results) — анализ течения, распространенности и исходов злокачественных новообразований
  • SPIO — суперпарамагнитные наночастицы оксида железа (superparamagnetic iron oxide nanoparticles)
  • TAD — таргетная подмышечная лимфодиссекция (Targeted Axillary Dissection)
  • TNM — Международная классификация стадий злокачественных новообразований (Tumor, Nodus, Metastasis)

При подготовке статей по раку молочной железы (РМЖ) в онкологии на сайте МедикалПланет использованы труды исключительно признанных зарубежных авторов:

  1. Celliers L, Mann GB. Alternative sites of injection for sentinel lymph node biopsy in breast cancer. ANZ J Surg. 2003;73(8):600-4. https://www.aerb.gov.in/images/PDF/NuclearMedicine/RSD1.pdf.
  2. Glass EC, Essner R, Morton DL. Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma. J Nucl Med. 1998;39:1185-90.
  3. Morton D, Cagle L, Wong J, et al. Intraoperative lymphatic mapping and selective lymphad-enectomy: technical details of a new procedure for clinical stage I melanoma. In: Presented at the annual meeting of the Society of Surgical Oncology, Washington, DC; 1990.
  4. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;392-99:392.
  5. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391-8.
  6. Chagpar AB, Scoggins CR, Martin RCG II, Carlson DJ, Laidley AL, El-Eid SE, McGlothin TQ, McMasters KM, for the University of Louisville Breast Sentinel Lymph Node Study Investigators. Are 3 sentinel nodes sufficient? Arch Surg. 2007;142:456-60.
  7. Krag DN, Anderson SJ, Julian TB, et al; National Surgical Adjuvant Breast and Bowel Project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8(10):881 -8.
  8. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-33.
  9. Ahmed M, Rubio IT, Kovacs T, Klimberg VS, Douek M. Systematic review of axillary reverse mapping in breast cancer. Br J Surg. 2016;103(3):170-8.
  10. Parmar V, Hawaldar R, Nair NS, et al. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer. Breast. 2013;22(6):1081 -6. https://doi.org/10.1016/j.breast.2013.06.006. pii: S0960-9776(13)00171-9. PubMed PMID: 23948301.
  11. Reddy A, Nair NS, Mokal S, et al. Can we avoid axillary lymph node dissection (ALND) in patients with 1 -2 positive sentinel/low axillary lymph nodes (SLN/LAS+) in the Indian setting? Indian J SurgOncol. 2o2i;12:272. https://doi.org/10.1007/s13193-021 -01297-6.
  12. Parmar V, Nair NS, Vanmali V, et al. Sentinel node biopsy versus low axillary sampling in predicting nodal status of postchemotherapy axilla in women with breast cancer. JCO Glob Oncol. 2020;6:1546-53.
  13. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455-61.
  14. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011 ;305(6):569-75.
  15. Galimberti V, Cole BF, Zurrida S, et al. International Breast Cancer Study Group. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297-305.
  16. Sola MS, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013;20:120-7.
  17. Savolt A, Musonda P, Matrai Z, et al. Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial. Orv Hetil. 2013;154:1934-42.
  18. Straver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 1098122023 AMAROS trial. Ann Surg Oncol. 2010;17:1854-61.
  19. Schmidt-Hansen M, et al. Axillary surgery in women with sentinel node-positive operable breast cancer: a systematic review with meta-analyses. Springerplus. 2016;5(1):85.
  20. Agarwal G, Gambhir S, Lal P, Krishnani N, Rajan S. Avoidance of axillary dissection in cN0 breast cancer patients with metastatic sentinel lymph node(s) using ACOSOG Z-0011 criteria: is it appropriate for Indian patients? J Clin Oncol. 2015;33(28 Suppl):62.
  21. Van la Parra RF, Peer PG, Ernst MF, et al. Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN. Eur J Surg Oncol. 2011;37:290-9.
  22. Toshikawa C, Koyama Y, Nagahashi M, et al. Predictive factors for non-sentinel lymph node metastasis in the case of positive sentinel lymph node metastasis in two or fewer nodes in breast cancer. J Clin Med Res. 2015;7:620-6.
  23. Gooch J, King TA, Eaton A. The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1-T2 breast cancer. Ann Surg Oncol. 2014;21:2897-903.
  24. Reddy A, Nair NS, Mokal S, et al. Validation of nomograms to predict non-sentinel lymph node metastasis after positive sentinel lymph node in breast cancer: Indian cohort background. J Clin Oncol. 2020;38(15_Suppl):568.
  25. Fisher B, et al. Twenty-five-year follow-up of a randomized trial comparing radical mas- tectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567-75.
  26. Krag DN, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph- node dissection in clinically nodenegative patients with breast cancer: overall survival find- ings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-33.
  27. Veronesi U, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546-53.
  28. Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303-10.
  29. Giuliano AE, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918-26.
  30. Fisher B, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483-93.
  31. van Nes JG, Putter H, Julien JP, et al. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat. 2009;115(1):101 -13.
  32. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, et al. European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrex- ate and fluorouracil (CMF). J Clin Oncol (Meeting Abstracts). 2005;23:513.
  33. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential pre- operative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165-74.
  34. Gianni L, Pienkowski T, Im Y-H, et al. 5-Year analysis of neoadjuvant pertuzumab and trastu- zumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791 -800.
  35. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6:676-84.
  36. Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezoli- zumab in combination with sequential nab-paclitaxel and anthracycline based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090-100.
  37. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147-59.
  38. von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. (KATHERINE). N Engl J Med. 2019;380:617-28.
  39. Zarebczan Dull B, Neuman HB. Management of the axilla. Surg Clin North Am. 2013;93:429-44.
  40. Rubio IT. Sentinel lymph node biopsy after neoadjuvant treatment in breast cancer: work in progress. Eur J Surg Oncol. 2016;42:326-32.
  41. Krishnamurthy S, et al. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer. 2002;95(5):982-8. https://doi.org/10.1002/cncr.10786.
  42. Tahir M, et al. Preoperative axillary staging in breast cancer—saving time and resources. Breast J. 2008;4:369.
  43. Alkuwari E, et al. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients. Cancer Cytopathol. 2008;114(2):89-93.
  44. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemo-therapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694-702.
  45. Kelly, et al. Sentinel node identification and classification after neoadjuvant chemotherapy—systematic review and metaanalysis. Acad Radiol. 2009;16:551 -63.
  46. Geng C, et al. The feasibility and accuracy of sentinel lymph node biopsy in initially clinically node-negative breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis. PLoS One. 2016;11(9):0162605.
  47. Hunt KK, Yi M, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558-66.
  48. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455-61.
  49. Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609-18.
  50. Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258-64.
  51. Classe J-M, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neo- adjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173(2):343-52.
  52. El Hage Chehade H, et al. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg. 2016;212(5):969-81.
  53. Caudle AS, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072-8.
  54. Donker M, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary stag- ing after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261(2):378-82.
  55. van Nijnatten TJA, et al. A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the Axilla with the sentinel node procedure (RISAS): a Dutch pro- spective multicenter validation study. Clin Breast Cancer. 2017;17:399-402.
  56. Swarnkar PK, et al. The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis. Cancers (Basel). 2021;13(7):1539.
  57. Galimberti V, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol. 2016;42(3):361 -8.
  58. Nogi H, et al. Long-term follow-up of node-negative breast cancer patients evaluated via sentinel node biopsy after neoadjuvant chemotherapy. Clin Breast Cancer. 2017;17(8):644-9.
  59. Kahler-Riberio-Fontana S, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur J Surg Oncol. 2021;47(4):804-12.
  60. Martelli G, et al. Sentinel node biopsy alone or with axillary dissection in breast cancer patients after primary chemotherapy: long-term results of a Prospective Interventional Study. Ann Surg. 2020;276:e544.
  61. Piltin MA, et al. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol. 2020;27(12):4795-801.
  62. Wong SM, et al. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol. 2021;28(5):2621 -9.
  63. Moo T-A, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Onco. 2018;25(6):1488-94.
  64. Escobedo JO, Rusin O, Lim S, Strongin RM. NIR dyes for bioimaging applications. Curr Opin Chem Biol. 2010;14(1 ):64-70. https://doi.Org/10.1016/j.cbpa.2009.10.022.
  65. Engel E, Schraml R, Maisch T, Kobuch K, Konig B, Szeimies R-M, Hillenkamp J, Baumler W, Vasold R. Light-induced decomposition of indocyanine green. Invest Ophthalmol Vis Sci. 2008;49(5):1777-83. https://doi.org/10.1167/iovs.07-0911.
  66. Kochubey VI, Kulyabina TV, Tuchin VV, Altshuler GB. Spectral characteristics of indocya- nine green upon its interaction with biological tissues. Opt Spectrosc. 2005;99(4):560-6. https://doi.org/10.1134/1.2113369.
  67. Nussbaum ES, Defillo A, Nussbaum L. The use of indocyanine green videoangiography to optimize the dural opening for intracranial parasagittal lesions. Neurosurgery. 2012;70(1 Suppl Operative):61-4. https://doi.org/10.1227/NEU.0b013e31822ecfeb.
  68. Park YM, Quan YH, Kwon KH, Cho J-G, Woo J-S, Kim B-M, Lee Y-S, Jeong JM, Kim HK, Song J-J. Endoscopic sentinel lymph node biopsy using indocyanine green-neomannosyl human serum albumin. Laryngoscope. 2018;128(4):E135-40. https://doi.org/10.1002/ lary.27036.
  69. Alander JT, Kaartinen I, Laakso A, Patila T, Spillmann T, Tuchin VV, Venermo M, Valisuo P. A review of indocyanine green fluorescent imaging in surgery. Int J Biomed Imaging. 2012;2012:940585. https://doi.org/10.1155/2012/940585.
  70. Motomura K, Inaji H, Komoike Y, Kasugai T, Noguchi S, Koyama H. Sentinel node biopsy guided by indocyanine green dye in breast cancer patients. Jpn J Clin Oncol. 1999;29(12):604-7. https://doi.org/10.1093/jjco/29.12.604.
  71. Kitai T, Inomoto T, Miwa M, Shikayama T. Fluorescence navigation with Indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005; 12(3):211 -5. https:// doi.org/10.2325/jbcs.12.211.
  72. Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol. 2014;15(8):e351 -62. https://doi.org/10.1016/ S1470-2045(13)70590-4.
  73. Sugie T, Kinoshita T, Masuda N, Sawada T, Yamauchi A, Kuroi K, Taguchi T, et al. Evaluation of the clinical utility of the ICG fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol. 2016;23(1):44-50. https:// doi.org/10.1245/s10434-015-4809-4.
  74. Zhang X, Li Y, Zhou Y, Mao F, Lin Y, Guan J, Sun Q. Diagnostic performance of Indocyanine green-guided sentinel lymph node biopsy in breast cancer: a meta-analysis. PLoS One. 2016;11(6):e0155597. https://doi.org/10.1371/journal.pone.0155597.
  75. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918-26. https://doi.org/10.1001/ jama.2017.11470.
  76. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997; 15(6):2345-50. https://doi.org/10.1200/JCO.1997.15.6.2345.
  77. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and senti- nel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391 -401. https://doi. org/10.1097/00000658-199409000-00015.
  78. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2(6):335-9; discussion 340. https://doi.org/10.1016/0960-7404(93)90064-6.
  79. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in earlystage breast carcinoma: a Meta-analysis. Cancer. 2006;106(1):4-16. https://doi.org/10.1002/ cncr.21568.
  80. Pesek S, Ashikaga T, Krag LE, Krag D. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg. 2012;36(9):2239-51. https://doi. org/10.1007/s00268-012-1623-z.
  81. Kedrzycki MS, Leiloglou M, Ashrafian H, Jiwa N, Thiruchelvam PTR, Elson DS, Leff DR. Meta-analysis comparing fluorescence imaging with radioisotope and blue dye-guided sentinel node identification for breast cancer surgery. Ann Surg Oncol. 2021;28(7):3738-48. https://doi.org/10.1245/s10434-020-09288-7.
  82. Mok CW, Tan SM, Zheng Q, Shi L. Network meta-analysis of novel and conventional senti- nel lymph node biopsy techniques in breast cancer. BJS Open. 2019;3(4):445-52. https://doi. org/10.1002/bjs5.50157.
  83. Goyal A. New technologies for sentinel lymph node detection. Breast Care. 2018;13(5):349-53. https://doi.org/10.1159/000492436.
  84. Karakatsanis A, Christiansen PM, Fischer L, Hedin C, Pistioli L, Sund M, Rasmussen NR, et al. The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparti- cles versus Tc(99) and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies. Breast Cancer Res Treat. 2016;157(2):281 -94. https://doi.org/10.1007/s10549-016-3809-9.
  85. Sever A, Jones S, Cox K, Weeks J, Mills P, Jones P. Preoperative localization of senti- nel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasonography in patients with breast cancer. Br J Surg. 2009;96(11 ):1295-9. https://doi.org/10.1002/ bjs.6725. PMID: 19847869.
  86. Omoto K. Futsuhara O. Sekine & M. Sakuragi. (2011). Sentinel node identification method using contrast-enhanced... https://www.umbjournal.org/article/S0301 -5629(11)00714-9/ fulltext.
  87. Cui Q, Dai L, Li J, Xue J. Accuracy of CEUS-guided sentinel lymph node biopsy in early- stage breast cancer: a study review and meta-analysis. World J Surg Oncol. 2020;18(1):1 —11. https://doi.org/10.1186/s12957-020-01890-z.
  88. Freeman WR, Bartsch DU, Mueller AJ, Banker AS, Weinreb RN. Simultaneous indocyanine green and fluorescein angiography using a confocal scanning laser ophthalmoscope. Arch Ophthalmol. 1998;116(4):455-63. https://doi.org/10.1001/archopht.116.4.455.
  89. Hope-Ross M, Yannuzzi LA, Gragoudas ES, Guyer DR, Slakter JS, Sorenson JA, Krupsky S, Orlock DA, Puliafito CA. Adverse reactions due to Indocyanine green. Ophthalmology. 1994;101(3):529-33. https://doi.org/10.1016/S0161-6420(94)31303-0.
  90. Yannuzzi LA, Rohrer KT, Tindel LJ, Sobel RS, Costanza MA, Shields W, Zang E. Fluorescein angiography complication survey. Ophthalmology. 1986;93(5):611-7. https://doi.org/10.1016/ s0161-6420(86)33697-2.
  91. Gurtner GC, Jones GE, Neligan PC, Newman MI, Phillips BT, Sacks JM, Zenn MR. Intraoperative laser angiography using the SPY system: review of the literature and recommendations for use. Ann Surg Innov Res. 2013;7(1):1. https://doi.org/10.1186/ 1750-1164-7-1.
  92. Goonawardena J, Yong C, Law M. Use of indocyanine green fluorescence compared to radioisotope for sentinel lymph node biopsy in early-stage breast cancer: systematic review and meta- analysis. Am J Surg. 2020;220(3):665-76. https://doi.org/10.1016/j.amjsurg.2020.02.001.
  93. Morrell ALG, Charles MA, Morrell-Junior MAC, Mendes JM, Tustumi F, Gioia Indocyanine green fluorescence imaging in robotic surgery: state of art, tips and tricks in current applications. Arq Gastroenterol. 2021 ;58(1):61 -70.
  94. Boileau J-F, Poirier B, Basik M, Holloway CMB, Gaboury L, Sideris L, Meterissian S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258 -64. https://doi.org/10.1200/ JCO.2014.55.7827.
  95. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Bret Taback A, Leitch M, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455-61. https://doi.org/10.1001/jama.2013.278932.
  96. Classe J-M, Cecile Loaec P, Gimbergues SA, Tunon C, de Lara PF, Dupre RR, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173(2):343-52. https://doi.org/10.1007/s10549-018-5004-7.
  97. Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadju- vant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609-18. https://doi.org/10.1016/S1470-2045(13)70166-9.
  98. Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3(4):549-55. https://doi.org/10.1001/jamaoncol.2016.4163.
  99. Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M, El-Tamer M, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with his- tologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467-74. https://doi.org/10.1245/s10434-016-5246-8.
  100. Tsuyuki S, Yamaguchi A, Senda N, Kawata Y, Kawaguchi K. Effect of neoadjuvant chemo- therapy on lymphatic pathways leading to sentinel lymph nodes in breast cancer. Cancer Cell Microenviron. 2015;2. https://doi.org/10.14800/ccm.850.
  101. Noguchi M, Noguchi M, Nakano Y, Ohno Y, Kosaka T. Axillary reverse mapping using a fluorescence imaging system in breast cancer. J Surg Oncol. 2012;105(3):229-34. https://doi. org/10.1002/jso.22094.
  102. Ikeda K, Ogawa Y, Komatsu H, Mori Y, Ishikawa A, Nakajima T, Oohira G, Tokunaga S, Fukushima H, Inoue T. Evaluation of the metastatic status of lymph nodes identified using axillary reverse mapping in breast cancer patients. World J Surg Oncol. 2012;10:233. https:// doi.org/10.1186/1477-7819-10-233.
  103. Sakurai T, Endo M, Shimizu K, Yoshimizu N, Nakajima K, Nosaka K, Dai Y, Iwao A, Jinnai Y. Axillary reverse mapping using fluorescence imaging is useful for identifying the risk group of postoperative lymphedema in breast cancer patients undergoing sentinel node biopsies. J Surg Oncol. 2014;109(6):612-5. https://doi.org/10.1002/jso.23528.
  104. Foster D, Choy N, Porter C, Ahmed S, Wapnir I. Axillary reverse mapping with Indocyanine green or isosulfan blue demonstrate similar crossover rates to radiotracer identified sentinel nodes. J Surg Oncol. 2018;117(3):336-40. https://doi.org/10.1002/jso.24859.
  105. Wu J-D, Wang Z, Zeng H-C, He L-F, Zhang Y-Q, Huang G-S, Zhang F, Wei X-L, Huang W-H, Zhang G-J. Comparison of indocyanine green and methylene blue use for axillary reverse mapping during axillary lymph node dissection. MedComm. 2020;1 (2):211 -8. https://doi. org/10.1002/mco2.31.
  106. Paskett ED, Dean JA, Oliveri JM, Phil J, Harrop. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J Clin Oncol. 2012;30(30):3726-33. https://doi. org/10.1200/JCO.2012.41.8574.
  107. Suami H. Anatomical theories of the pathophysiology of cancer-related lymphoedema. Cancers. 2020;12(5):1338. https://doi.org/10.3390/cancers12051338.
  108. Heydon-White A, Suami H, Boyages J, Koelmeyer L, Peebles KC. Assessing breast lymph- oedema following breast cancer treatment using indocyanine green lymphography. Breast Cancer Res Treat. 2020;181(3):635-44. https://doi.org/10.1007/s10549-020-05661 -y.
  109. Anker AM, Prantl L, Strauss C, Brebant V, Schenkhoff F, Pawlik M, Vykoukal J, Klein SM. Assessment of DIEP flap perfusion with intraoperative Indocyanine green fluorescence imaging in vasopressor-dominated hemodynamic support versus Liberal fluid administration: a randomized controlled trial with breast cancer patients. Ann Surg Oncol. 2020;27(2):399-406. https://doi.org/10.1245/s10434-019-07758-1.
  110. Ludolph I, Arkudas A, Schmitz M, Boos AM, Taeger CD, Rother U, Horch RE, Beier JP. Cracking the perfusion code?: laser-assisted indocyanine green angiography and combined laser Doppler spectrophotometry for intraoperative evaluation of tissue perfusion in autolo- gous breast reconstruction with DIEP or Ms-TRAM flaps. J Plast Reconstruct Aesth Surg. 2016;69(10):1382-8. https://doi.org/10.1016/j.bjps.2016.07.014.
  111. Liu DZ, Mathes DW, Zenn MR, Neligan PC. The application of indocyanine green fluores- cence angiography in plastic surgery. J Reconstr Microsurg. 2011 ;27(6):355-63. https://doi. org/10.1055/s-0031-1281515.
  112. Diep GK, Hui JYC, Marmor S, Cunningham BL, Choudry U, Portschy PR, Tuttle TM. Postmastectomy reconstruction outcomes after intraoperative evaluation with indocya- nine green angiography versus clinical assessment. Ann Surg Oncol. 2016;23(12):4080-5. https://doi.org/10.1245/s10434-016-5466-y.
  113. Krishnan KG, Schackert G, Steinmeier R. The role of near-infrared angiography in the assessment of post-operative venous congestion in random pattern, pedicled Island and free flaps. Br J Plast Surg. 2005;58(3):330-8. https://doi.org/10.1016/j.bjps.2004.10.003.
  114. Moyer HR, Losken A. Predicting mastectomy skin flap necrosis with Indocyanine green angiography: the gray area defined. Plast Reconstr Surg. 2012;129(5):1043-8. https://doi. org/10.1097/PRS.0b013e31824a2b02.
  115. Reinhart MB, Huntington CR, Blair LJ, Todd Heniford B, Augenstein VA. Indocyanine green: historical context, current applications, and future considerations. Surg Innov. 2016;23(2):166-75. https://doi.org/10.1177/1553350615604053.
  116. Knackstedt R, Couto RA, Ko J, Cakmakoglu C, Daisy W, Gastman B. Indocyanine green fluorescence imaging with lymphoscintigraphy for sentinel node biopsy in melanoma: increasing the sentinel lymph node-positive rate. Ann Surg Oncol. 2019;26(11):3550-60. https://doi. org/10.1245/s10434-019-07617-z.
  117. Umberto V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546.
  118. Krag DN, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph- node dissection in clinically nodenegative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927-33.
  119. Mansel RE, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599-609.
  120. Krag D, et al. The sentinel node in breast cancer--a multicenter validation study. N Engl J Med. 1998;339:941 -6.
  121. Giuliano AE, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-75.
  122. Bergkvist L, Frisell J. Multicentre validation study of sentinel node biopsy for staging in breast cancer. Br J Surg. 2005;92:1221-4.
  123. Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303-10.
  124. WHO. Breast cancer: prevention and control. WHO http://www.who.int/cancer/detection/ breastcancer/en/.
  125. Barthelmes L, et al. Adverse reactions to patent blue V dye — the NEW START and ALMANAC experience. Eur J Surg Oncol. 2010;36:399-403.
  126. Masannat Y, Shenoy H, Speirs V, Hanby A, Horgan K. Properties and characteristics of the dyes injected to assist axillary sentinel node localization in breast surgery. Eur J Surg Oncol. 2006;32:381 -4.
  127. Samorani D, et al. The use of indocyanine green to detect sentinel nodes in breast cancer: a prospective study. Eur J Surg Oncol J. 2015;41:64-70.
  128. Wishart GC, Loh S-W, Jones L, Benson JR. A feasibility study (ICG-10) of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer. Eur J Surg Oncol. 2012;38:651 -6.
  129. Ballardini B, et al. The indocyanine green method is equivalent to the 99mTc-labeled radio- tracer method for identifying the sentinel node in breast cancer: a concordance and validation study. Eur J Surg Oncol J. 2013;39:1332-6.
  130. Hojo T, Nagao T, Kikuyama M, Akashi S, Kinoshita T. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer. Breast. 2010;19:210-3.
  131. Murawa D, Hirche C, Dresel S, Hunerbein M. Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence. Br J Surg. 2009;96:1289-94.
  132. Polom K, Murawa D, Nowaczyk P, Rho YS, Murawa P. Breast cancer sentinel lymph node mapping using near infrared guided indocyanine green and indocyanine green--human serum albumin in comparison with gamma emitting radioactive colloid tracer. Eur J Surg Oncol. 2012;38:137-42.
  133. Sugie T, et al. Evaluation of the clinical utility of the ICG fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol. 2016;23:44-50.
  134. Papathemelis T, et al. Sentinel lymph node biopsy in breast cancer patients by means of Indocyanine green using the Karl Storz VITOM® fluorescence camera. Biomed Res Int. 2018;2018:6251468.
  135. Chang YW, et al. Sentinel lymph node detection using fluorescein and blue light-emitting diodes in patients with breast carcinoma: a single-center prospective study. Asian J Surg. 2020;43:220-6.
  136. Mazouni C, et al. Prospective evaluation of the limitations of near-infrared imaging in detecting axillary sentinel lymph nodes in primary breast cancer. Breast J. 2018;24:1006-9.
  137. Tagaya N, et al. Intraoperative identification of sentinel lymph nodes by near-infrared fluores- cence imaging in patients with breast cancer. Am J Surg. 2008;195:850-3.
  138. Toh U, et al. Navigation surgery for intraoperative sentinel lymph node detection using Indocyanine green (ICG) fluorescence real-time imaging in breast cancer. Breast Cancer Res Treat. 2015;153:337-44.
  139. Tong M, Guo W, Gao W. Use of fluorescence imaging in combination with patent blue dye versus patent blue dye alone in sentinel lymph node biopsy in breast cancer. J Breast Cancer. 2014;17:250-5.
  140. Abe H, et al. Indocyanine green fluorescence imaging system for sentinel lymph node biopsies in early breast cancer patients. Surg Today. 2011 ;41:197-202.
  141. He K, et al. Comparison between the indocyanine green fluorescence and blue dye methods for sentinel lymph node biopsy using novel fluorescence image-guided resection equipment in different types of hospitals. Transl Res J Lab Clin Med. 2016;178:74-80.
  142. Liu J, Huang L, Wang N, Chen P. Indocyanine green detects sentinel lymph nodes in early breast cancer. J Int Med Res. 2017;45:514-24.
  143. Pitsinis V, Provenzano E, Kaklamanis L, Wishart GC, Benson JR. Indocyanine green fluorescence mapping for sentinel lymph node biopsy in early breast cancer. Surg Oncol. 2015;24:375-9.
  144. Hokimoto N, et al. A novel color fluorescence navigation system for intraoperative transcutaneous lymphatic mapping and resection of sentinel lymph nodes in breast cancer: comparison with the combination of gamma probe scanning and visible dye methods. Oncology. 2018;94:99-106.
  145. Guo W, et al. Breast cancer sentinel lymph node mapping using near-infrared guided indocyanine green in comparison with blue dye. Tumour Biol. 2014;35:3073-8.
  146. Guo J, et al. Comparison of sentinel lymph node biopsy guided by indocyanine green, blue dye, and their combination in breast cancer patients: a prospective cohort study. World J Surg Oncol. 2017;15:196.
  147. Hirano A, et al. A comparison of indocyanine green fluorescence imaging plus blue dye and blue dye alone for sentinel node navigation surgery in breast cancer patients. Ann Surg Oncol. 2012;19:4112-6.
  148. Schaafsma BE, et al. Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer. Br J Surg. 2013;100:1037-44.
  149. Valente SA, et al. Near infrared fluorescent lymph node mapping with Indocyanine green in breast cancer patients: a prospective trial. J Am Coll Surg. 2019;228:672-8.
  150. Vermersch C, Raia-Barjat T, Chapelle C, Lima S, Chauleur C. Randomized comparison between indocyanine green fluorescence plus 99mtechnetium and 99mtechnetium alone methods for sentinel lymph node biopsy in breast cancer. Sci Rep. 2019;9:6943.
  151. Shiozawa M, et al. Sentinel lymph node biopsy in patients with breast cancer using superparamagnetic iron oxide and a magnetometer. Breast Cancer. 2013;20:223-9.
  152. Douek M, et al. Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG Multicentre Trial. Ann Surg Oncol. 2014;21:1237-45.
  153. Rubio IT, et al. The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancer. Eur J Surg Oncol. 2015;41:46-51.
  154. Thill M, et al. The Central-European SentiMag study: sentinel lymph node biopsy with super- paramagnetic iron oxide (SPIO) vs. radioisotope. Breast. 2014;23:175-9.
  155. Pinero-Madrona A, et al. Superparamagnetic iron oxide as a tracer for sentinel node biopsy in breast cancer: a comparative non-inferiority study. Eur J Surg Oncol. 2015;41:991 -7.
  156. Ghilli M, et al. The superparamagnetic iron oxide tracer: a valid alternative in sentinel node biopsy for breast cancer treatment. Eur J Cancer Care. 2017;26.
  157. Karakatsanis A, et al. The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc(99) and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies. Breast Cancer Res T reat. 2016;157:281 -94.
  158. Houpeau J-L, et al. Sentinel lymph node identification using superparamagnetic iron oxide particles versus radioisotope: the French Sentimag feasibility trial. J Surg Oncol. 2016;113:501 -7.
  159. Coufal O, Fait V, Lzicarova E, Chrenko V, Zaloudik J. [SentiMag--the magnetic detection system of sentinel lymph nodes in breast cancer]. Rozhl V Chir Mesicnik Ceskoslovenske Chir Spolecnosti. 2015;94:283-8.
  160. Alvarado MD, et al. SentimagIC: a non-inferiority trial comparing superparamagnetic iron oxide versus technetium-99m and blue dye in the detection of axillary sentinel nodes in patients with early-stage breast cancer. Ann Surg Oncol. 2019;26:3510-6.
  161. Hamzah JL, et al. A pilot study comparing Sentimag/Sienna versus standard modality for sentinel lymph node identification in patients with breast cancer. Breast J. 2020;26:1074-7.
  162. Taruno K, et al. Multicenter clinical trial on sentinel lymph node biopsy using superparamagnetic iron oxide nanoparticles and a novel handheld magnetic probe. J Surg Oncol. 2019;120:1391 -6.
  163. Rubio IT, Rodriguez-Revuelto R, Espinosa-Bravo M, Siso C, Rivero J, Esgueva A. A randomized study comparing different doses of superparamagnetic iron oxide tracer for sentinel lymph node biopsy in breast cancer: the SUNRISE study. Eur J Surg Oncol. 2020;46:2195-201.
  164. Hersi AF, et al. Optimizing dose and timing in magnetic tracer techniques for sentinel lymph node detection in early breast cancers: the prospective multicenter Sentidose trial. Cancers. 2021;13:693.
  165. Karakatsanis A, et al. Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study). Br J Surg. 2019;106:720-8.
  166. Pantiora E, et al. Evolution and refinement of magnetically guided sentinel lymph node detection in breast cancer: metaanalysis. Br J Surg. 2023;110:410. https://doi.org/10.1093/bjs/ znac426.
  167. Karakatsanis A, et al. Delayed sentinel lymph node dissection in patients with a preoperative diagnosis of ductal cancer in situ by preoperative injection with superparamagnetic iron oxide (SPIO) nanoparticles: The SentiNot Study. Ann Surg Oncol. 2023; https://doi.org/10.1245/ s10434-022-13064-0. Epub ahead of print.
  168. Omoto K, et al. Sentinel node detection in breast cancer using contrast-enhanced sonography with 25% albumin--initial clinical experience. J Clin Ultrasound. 2006;34:317-26.
  169. Li J, et al. How pre-operative sentinel lymph node contrast-enhanced ultrasound helps intraoperative sentinel lymph node biopsy in breast cancer: initial experience. Ultrasound Med Biol. 2019;45:1865-73.
  170. Sever AR, et al. Preoperative localization of sentinel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasonography in patients with breast cancer. Br J Surg. 2009;96:1295-9.
  171. Omoto K, et al. Sentinel node detection method using contrast-enhanced ultrasonography with sonazoid in breast cancer: preliminary clinical study. Ultrasound Med Biol. 2009;35:1249-56.
  172. Sever AR, et al. Preoperative sentinel node identification with ultrasound using microbubbles in patients with breast cancer. AJR Am J Roentgenol. 2011 ;196:251 -6.
  173. Sever AR, et al. Preoperative needle biopsy of sentinel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasound in patients with breast cancer. AJR Am J Roentgenol. 2012;199:465-70.
  174. Hu H, Wei W, Sun D, Liu Y. [Clinical application of sentinel lymph node biopsy under the guidance of contrast-enhanced ultrasound plus methylene blue in patients with breast cancer]. Zhonghua Yi Xue Za Zhi. 2013;93:1255-7.
  175. Barentsz MW, et al. Sentinel lymph node localization with contrast-enhanced ultrasound and an I-125 seed: an ideal prospective development study. Int J Surg Lond. 2015;14:1 -6.
  176. Matsuzawa F, et al. Accurate diagnosis of axillary lymph node metastasis using contrast-enhanced ultrasonography with Sonazoid. Mol Clin Oncol. 2015;3:299-302.
  177. Xie F, et al. Intradermal microbubbles and contrast-enhanced ultrasound (CEUS) is a feasible approach for sentinel lymph node identification in early-stage breast cancer. World J Surg Oncol. 2015;13:319.
  178. Eshefani, et al. Validation of contrast enhanced ultrasound technique to wire localization of sentinel lymph node in patients with early breast cancer. Indian J Surg Oncol. 2015;6. https://pubmed-ncbi-nlm-nih-gov.ezproxy.its.uu.se/27065663/?utm_source=gquery&utm_ medium=referral&utm_campaign=CitationSensor.
  179. Rautiainen S, et al. Contrast-enhanced ultrasound -guided axillary lymph node core biopsy: diagnostic accuracy in preoperative staging of invasive breast cancer. Eur J Radiol. 2015;84:2130-6.
  180. Britton P, et al. Microbubble detection and ultrasound-guided vacuum-assisted biopsy of axil- lary lymph nodes in patients with breast cancer. Clin Radiol. 2017;72:772-9.
  181. Shimazu K, et al. Identification of sentinel lymph nodes by contrast-enhanced ultrasonography with Sonazoid in patients with breast cancer: a feasibility study in three hospitals. Cancer Med. 2017;6:1915-22.
  182. Wang Y, et al. Variation of sentinel lymphatic channels (SLCs) and sentinel lymph nodes (SLNs) assessed by contrast-enhanced ultrasound (CEUS) in breast cancer patients. World J Surg Oncol. 2017;15:127.
  183. Cox K, et al. Enhanced pre-operative axillary staging using intradermal microbubbles and contrast-enhanced ultrasound to detect and biopsy sentinel lymph nodes in breast cancer: a potential replacement for axillary surgery. Br J Radiol. 2018;91:20170626.
  184. Zhao J, et al. The value of contrast-enhanced ultrasound for sentinel lymph node identification and characterisation in preoperative breast cancer patients: a prospective study. Eur Radiol. 2018;28:1654-61.
  185. Zhong J, et al. Contrast-enhanced ultrasound-guided fine-needle aspiration for sentinel lymph node biopsy in early-stage breast cancer. Ultrasound Med Biol. 2018;44:1371-8.
  186. Liu J, et al. Percutaneous contrast-enhanced ultrasound for localization and diagnosis of sentinel lymph node in early breast cancer. Sci Rep. 2019;9:13545.
  187. Dellaportas D, et al. Contrast-enhanced color Doppler ultrasonography for preoperative evaluation of sentinel lymph node in breast cancer patients. Breast Care. 2015;10:331 -5.
  188. Saidha NK, Aggarwal R, Sen A. Identification of sentinel lymph nodes using contrast-enhanced ultrasound in breast cancer. Indian J Surg Oncol. 2018;9:355-61.
  189. Mok CW, Tan S-M, Zheng Q, Shi L. Network meta-analysis of novel and conventional sentinel lymph node biopsy techniques in breast cancer. BJS Open. 2019;3:445-52.
  190. Goyal A. New technologies for Sentinel lymph node detection. Breast Care. 2018;13:349-53.
  191. Motomura K, Izumi T, Tateishi S, Tamaki Y, Ito Y, Horinouchi T, Nakanishi K. Superparamagnetic iron oxide-enhanced MRI at 3 T for accurate axillary staging in breast cancer. Br J Surg. 2016;103(1):60 - 9.
  192. Jazrawi A, Pantiora E, Abdsaleh S, et al. Magnetic-Guided Axillary UltraSound (MagUS) Sentinel lymph node biopsy and mapping in patients with early breast cancer. a phase 2, single- arm prospective clinical trial. Cancers (Basel). 2021 ;13(17):4285. https://doi.org/10.3390/cancers13174285. Published 2021 Aug 25.
  193. Axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918-26. https://doi.org/10.1001/jama.2017.11470. PMID: 28898379; PMCID: PMC5672806.
  194. Jorns JM, Kidwell KM. Sentinel lymph node frozen-section utilization declines after publication of American College of Surgeons oncology group Z0011 trial results with no change in subsequent surgery for axillary lymph node dissection. Am J Clin Pathol. 2016;146(1):57-66. https://doi.org/10.1093/ajcp/aqw078. Epub 2016 Jul 3. PMID: 27373347.
  195. Somashekhar SP, Naikoo ZA, Zaveri SS, Holla S, Chandra S, Mishra S, Parameswaran RV. Intraoperative frozen section evaluation of sentinel lymph nodes in breast carcinoma: single-institution Indian experience. Indian J Surg. 2015;77(Suppl 2):335-40. https://doi.org/10.1007/s12262-013-0827-2. Epub 2013 Feb 5. PMID: 26730021; PMCID: PMC4692900.
  196. Wong J, Yong WS, Thike AA, Iqbal J, Salahuddin AS, Ho Gh, Madhukumar P, Tan BK, Ong KW, Tan PH. False negative rate for intraoperative sentinel lymph node frozen section in patients with breast cancer: a retrospective analysis of patients in a single Asian institution. J Clin Pathol. 2015;68(7):536-40. https://doi.org/10.1136/jclinpath-2014-202799. Epub 2015 Apr 8. PMID: 25855801.
  197. Iacuzzo C, Scomersi S, Giudici F, Bonadio L, Troian M, Bellio G, Rizzardi C, Bonazza D, Zanconati F, Bortul M. The current role of touch imprint cytology in sentinel lymph node intra-operatory examination. Breast J. 2020;26(3):576-7. https://doi.org/10.1111/tbj.13619. Epub 2019 Sep 4. PMID: 31486216.
  198. Shi F, Liang Z, Zhang Q, Wang C, Liu X. The performance of one-step nucleic acid amplification assay for intraoperative detection of sentinel lymph node macrometastasis in breast cancer: an updated meta-analysis. Breast. 2018;39:39-45. https://doi.org/10.10167j.breast.2018.03.005. Epub 2018 Mar 22. PMID: 29574393.
  199. Lowes S, Leaver A, Cox K, Satchithananda K, Cosgrove D, Lim A. Evolving imaging techniques for staging axillary lymph nodes in breast cancer. Clin Radiol. 2018;73(4):396-409. https://doi.org/10.1016/j.crad.2018.01.003. Epub 2018 Feb 10. PMID: 29439780.
  200. Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Har-low SP, Julian TB, Mamounas EP, Wolmark N. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412-21. https://doi.org/10.1056/NEJMoa1008108.
  201. Klevesath MB, Bobrow LG, Pinder SE, Purushotham AD. The value of immunohistochemistry in sentinel lymph node histopathology in breast cancer. Br J Cancer. 2005;92(12):2201-5. https://doi.org/10.1038/sj.bjc.6602641. PMID: 15942633; PMCID: PMC2361824.
  202. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-22. https://doi.org/10.1200/JCO.2007.10.6823. Epub 2007 Sep 4. PMID: 17785706.
  203. Sacre RA. Clinical evaluation of axillar lymph nodes compared to surgical and pathological findings. Eur J Surg Oncol. 1986;12(2):169-73.
  204. Cooper KL, Meng Y, Harnan S, Ward SE, Fitzgerald P, Papaioannou D, et al. Positron emis- sion tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2011;15(4):iii-v, 1-134. https://doi.org/10.3310/hta15040.
  205. Hwang SO, Lee SW, Kim HJ, Kim WW, Park HY, Jung JH. The comparative study of ultraso- nography, contrast-enhanced MRI, and (18)F-FDG PET/CT for detecting axillary lymph node metastasis in T1 breast cancer. J Breast Cancer. 2013;16(3):315-21. https://doi.org/10.4048/ jbc.2013.16.3.315; Epub 2013 Sep 30.
  206. Caudle AS, Cupp JA, Kuerer HM. Management of axillary disease. Surg Oncol Clin N Am. 2014;23(3):473-86. https://doi.org/10.1016/j.soc.2014.03.007; Epub 2014 Apr 13.
  207. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radio localization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2(6):335-9; discussion 340. https://doi.org/10.1016/0960-7404(93)90064-6.
  208. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymph- adenectomy for breast cancer. Ann Surg. 1994;220(3):391 -8; discussion 398-401. https://doi. org/10.1097/00000658-199409000-00015.
  209. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276(22):1818-22.
  210. Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detec- tion. J Am Coll Surg. 1998;186(3):275-83. https://doi.org/10.1016/s1072-7515(98)00011 -8.
  211. Radovanovic Z, Golubovic A, Plzak A, Stojiljkovic B, Radovanovic D. Blue dye versus com- bined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast can- cer. Eur J Surg Oncol. 2004;30(9):913-7. https://doi.org/10.1016/j.ejso.2004.08.003.
  212. Syme DB, Collins JP, Mann GB. Comparison of blue dye and isotope with blue dye alone in breast sentinel node biopsy. ANZ J Surg. 2005;75(9):817-21. https://doi. org/10.1111/j.1445-2197.2005.03531.x.
  213. Hung WK, Chan CM, Ying M, Chong SF, Mak KL, Yip AW. Randomized clinical trial compar- ing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. Br J Surg. 2005;92(12):1494-7. https://doi.org/10.1002/bjs.5211.
  214. Goyal A, Newcombe RG, Chhabra A, Mansel RE. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer-results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99(2):203-8. https://doi.org/10.1007/ s10549-006-9192-1.
  215. Ghiassi S, Sun YS, Kim VB, Scott CM, Nifong LW, Rotondo MF, et al. Methylene blue enhance- ment of resuscitation after refractory haemorrhagic shock. J Trauma. 2004;57(3):515-21. https://doi.org/10.1097/01 .ta.0000136159.22721.3d.
  216. Li J, Chen X, Qi M, Li Y. Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: a systematic review and meta-analysis. PLoS One. 2018;13(9):e0204364. https://doi.org/10.1371/journal.pone.0204364.
  217. Han C, Yang L, Zuo W. A mini-review on factors and countermeasures associated with false- negative sentinel lymph node biopsies in breast cancer. Chin J Cancer Res. 2016;28(3):370-6. https://doi.org/10.21147Zj.issn.1000-9604.2016.03.12.
  218. Peek MC, Charalampoudis P, Anninga B, Baker R, Douek M. Blue dye for identification of sentinel nodes in breast cancer and malignant melanoma: a systematic review and meta- analysis. Future Oncol. 2017;13(5):455-67. https://doi.org/10.2217/fon-2016-0255; Epub 2016 Aug 31.
  219. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. National Surgical Adjuvant Breast and bowel project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881 - 8.https://doi.org/10.1016/S1470-2045(07)70278-4.
  220. Raut CP, Hunt KK, Akins JS, Daley MD, Ross MI, Singletary SE, et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice proto- col. Cancer. 2005;104(4):692-9. https://doi.org/10.1002/cncr.21226.
  221. Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective interna- tional cooperative group trial. Ann Surg Oncol. 2006;13(4):491 -500. https://doi.org/10.1245/ ASO.2006.05.013; Epub 2006 Mar 2.
  222. Perenyei M, Barber ZE, Gibson J, Hemington-Gorse S, Dobbs TD. Anaphylactic reaction rates to blue dyes used for sentinel lymph node mapping: systematic review and meta-analysis. Ann Surg. 2021;273(6):1087-93. https://doi.org/10.1097/SLA.0000000000004061.
  223. Brahma B, Putri RI, Karsono R, Andinata B, Gautama W, Sari L, et al. The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy: a study from Dharmais cancer hospital. World J Surg Oncol. 2017;15(1):41. https://doi.org/10.1186/ s12957-017-1113-8.
  224. Zhang GC, Liao N, Guo ZB, Qian XK, Ren CY, Yao M, et al. Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience. Clin Transl Oncol. 2013;15(1):79-84. https://doi.org/10.1007/s12094-012-0885-0; Epub 2012 Aug 28.
  225. Bleicher RJ, Kloth DD, Robinson D, Axelrod P. Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy. J Surg Oncol. 2009;99(6):356-60. https://doi.org/10.1002/jso.21240.
  226. Teknos D, Ramcharan A, Oluwole SF. Pulmonary edema associated with methylene blue dye administration during sentinel lymph node biopsy. J Natl Med Assoc. 2008;100(12):1483-4. https://doi.org/10.1016/s0027-9684(15)31552-2.
  227. Zakaria S, Hoskin TL, Degnim AC. Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. Am J Surg. 2008;196(2):228-33. https://doi.org/10.1016/j. amjsurg.2007.08.060.
  228. Li N, Wang X, Lin B, Zhu H, Liu C, Xu X, et al. Clinical evaluation of 99mTc-rituximab for sentinel lymph node mapping in breast cancer patients. J Nucl Med. 2016;57(8):1214-20. https://doi.org/10.2967/jnumed.115.160572; Epub 2016 Mar 16.
  229. Ilem-Ozdemir D, Yararbas U, Zengel B, Ertan G, Asikoglu M. Preparation of 99mTc-isosulfan blue for lymph node localization in rats 99mTc-isosulfan blue for lymph node localization. Appl Radiat Isot. 2016;118:338-42. https://doi.org/10.1016/j.apradiso.2016.10.007; Epub 2016 Oct 11.
  230. Nieweg OE, Jansen L, Valdes Olmos RA, Rutgers EJ, Peterse JL, Hoefnagel KA, et al. Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Eur J Nucl Med. 1999;26(4 Suppl):S11-6. https://doi.org/10.1007/s002590050572.
  231. Sappey MPC. Injection preparation et conservation des vaisseaux lymphatiques. These pour le doctorat en medecine. No. 241. Paris: Rignoux Imprimeur de la Faculte de Medecine; 1834.
  232. Pelosi E, Bello M, Giors M, Ala A, Giani R, Bussone R, et al. Sentinel lymph node detection in patients with early-stage breast cancer: comparison of periareolar and subdermal/peritumoral injection techniques. J Nucl Med. 2004;45(2):220-5.
  233. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997; 15(6):2345-50. https://doi.org/10.1200/JCO.1997.15.6.2345.
  234. Cox K, Sever A, Jones S, Weeks J, Mills P, Devalia H, et al. Validation of a technique using microbubbles and contrast enhanced ultrasound (CEUS) to biopsy sentinel lymph nodes (SLN) in pre-operative breast cancer patients with a normal greyscale axillary ultrasound. Eur J Surg Oncol. 2013;39(7):760-5. https://doi.org/10.1016/j.ejso.2013.03.026; Epub 2013 Apr 28.
  235. Kern KA. Concordance and validation study of sentinel lymph node biopsy for breast cancer using subareolar injection of blue dye and technetium 99m sulfur colloid. J Am Coll Surg. 2002;195(4):467-75. https://doi.org/10.1016/s1072-7515(02)01312-1.
  236. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349(9069):1864-7. https://doi.org/10.1016/S0140-6736(97)01004-0.
  237. Rodier JF, Velten M, Wilt M, Martel P, Ferron G, Vaini-Elies V, et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol. 2007;25(24):3664-9. https://doi.org/10.1200/JCO.2006.08.4228; Epub 2007 May 7.
  238. Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg. 2000;232(1):81 -9. https://doi.org/10.1097/00000658-200007000-00012.
  239. Bauer TW, Bedrosian I, Spitz F, et al Subareolar injection simplifies sentinel lymph node map- ping for breast cancer [Abstract]. Society of surgical oncology 54th annual cancer symposium; 2001 March 15-18; Washington, DC: Abstract 71.
  240. Mudun A, Sanli Y, Ozmen V, Turkmen C, Ozel S, Eroglu A, et al. Comparison of different injection sites of radionuclide for sentinel lymph node detection in breast cancer: sin- gle institution experience. Clin Nucl Med. 2008;33(4):262-7. https://doi.org/10.1097/ RLU.0b013e3181662fc7.
  241. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703-20. https://doi.org/10.1200/JCO.2005.08.001; Epub 2005 Sep 12.
  242. Shimazu K, Tamaki Y, Taguchi T, Motomura K, Inaji H, Koyama H, et al. Lymphoscintigraphic visualization of internal mammary nodes with subtumoral injection of radiocolloid in patients with breast cancer. Ann Surg. 2003;237(3):390-8. https://doi.org/10.1097/01. SLA.0000055226.89022.90.
  243. Tanis PJ, Deurloo EE, Valdes Olmos RA, Rutgers EJ, Nieweg OE, Besnard AP, et al. Single intralesional tracer dose for radioguided excision of clinically occult breast cancer and sen- tinel node. Ann Surg Oncol. 2001 ;8(10):850-5. https://doi.org/10.1007/s10434-001 -0850-6.
  244. Doting MH, Jansen L, Nieweg OE, Piers DA, Tiebosch AT, Koops HS, et al. Lymphatic mapping with intralesional tracer administration in breast carcinoma patients. Cancer. 2000;88(11):2546-52.
  245. van der Ploeg IM, Tanis PJ, Valdes Olmos RA, Kroon BB, Rutgers EJ, Nieweg OE. Breast cancer patients with extra-axillary sentinel nodes only may be spared axillary lymph node dissection. Ann Surg Oncol. 2008;15(11):3239-43. https://doi.org/10.1245/s10434-008-0120-y; Epub 2008 Sep 5.
  246. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer--a multicenter validation study. N Engl J Med. 1998;339(14):941 -6. https://doi. org/10.1056/NEJM199810013391401.
  247. Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999;91(4):368-73. https://doi.org/10.1093/jnci/91.4.368.
  248. Miner TJ, Shriver CD, Flicek PR, Miner FC, Jaques DP, Maniscalco-Theberge ME, et al. Guidelines for the safe use of radioactive materials during localization and resection of the sentinel lymph node. Ann Surg Oncol. 1999;6(1):75-82. https://doi.org/10.1007/ s10434-999-0075-7.
  249. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 1998;227(5):645-51; discussion 651 -3. https://doi.org/10.1097/00000658-199805000-00005.
  250. McMasters KM, Wong SL, Tuttle TM, Carlson DJ, Brown CM, Dirk Noyes R, et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes. Ann Surg. 2000;231 (5):724-31. https://doi. org/10.1097/00000658-200005000-00013.
  251. Burak WE Jr, Walker MJ, Yee LD, Kim JA, Saha S, Hinkle G, et al. Routine preoperative lym- phoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer. Am J Surg. 1999;177(6):445-9. https://doi.org/10.1016/s0002-9610(99)00088-4.
  252. Wang L, Yu JM, Wang YS, Zuo WS, Gao Y, Fan J, Li JY, Hu XD, Chen ML, Yang GR, Zhou ZB, Liu YS, Li YQ, Liu YB, Zhao T, Chen P. Preoperative lymphoscintigraphy predicts the successful identification but is not necessary in sentinel lymph nodes biopsy in breast can- cer. Ann Surg Oncol. 2007;14(8):2215-20. https://doi.org/10.1245/s10434-007-9418-4; Epub 2007 May 24.
  253. Martin RC 2nd, Edwards MJ, Wong SL, Tuttle TM, Carlson DJ, Brown CM, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery. 2000;128(2):139-44. https://doi.org/10.1067/msy.2000.108064.
  254. Chung A, Yu J, Stempel M, Patil S, Cody H, Montgomery L. Is the «10% rule» equally valid for all subsets of sentinel-nodepositive breast cancer patients? Ann Surg Oncol. 2008;15(10):2728-33. https://doi.org/10.1245/s10434-008-0050-8; Epub 2008 Aug 8.
  255. American Joint Committee on Cancer. In: Edge SB, editor. Cancer staging manual. 7th ed. New York: Springer; 2010. p. 347.
  256. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast cancer- major changes in the American Joint Committee on Cancer eighth edition cancer staging man- ual. CA Cancer J Clin. 2017;67(4):290-303. https://doi.org/10.3322/caac.21393; Epub 2017 Mar 14. Erratum in: CA Cancer J Clin. 2017 Jul 8;67(4):345.
  257. Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of occult metastases on survival in nodenegative breast cancer. N Engl J Med. 2011 ;364(5):412-21. https://doi.org/10.1056/NEJMoa1008108; Epub 2011 Jan 19.
  258. Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011 ;306(4):385-93. https:// doi.org/10.1001/jama.2011.1034.
  259. Choi AH, Surrusco M, Rodriguez S, Bahjri K, Solomon N, Garberoglio C, et al. Extranodal extension on sentinel lymph node dissection: why should we treat it differently? Am Surg. 2014;80(10):932-5.
  260. Changsri C, Prakash S, Sandweiss L, Bose S. Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery. Breast J. 2004;10(5):392-7. https://doi. org/10.1111/j.1075-122X.2004.21446.x.
  261. Abdessalam SF, Zervos EE, Prasad M, Farrar WB, Yee LD, Walker MJ, et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg. 2001;182(4):316-20. https://doi.org/10.1016/s0002-9610(01 )00719-x.
  262. McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18(13):2560-6. https://doi.org/10.1200/JCO.2000.18.13.2560.
  263. Klauber-DeMore N, Bevilacqua JL, Van Zee KJ, Borgen P, Cody HS 3rd. Comprehensive review of the management of internal mammary lymph node metastases in breast cancer. J Am Coll Surg. 2001 ;193(5):547-55. https://doi.org/10.1016/s1072-7515(01 )01040-7.
  264. Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel medical center sentinel node multicenter study. J Am Coll Surg. 2009;208(3):333-40. https://doi.org/10.1016/jjamcollsurg.2008.10.036; Epub 2008 Dec 25.
  265. Chagpar A, Middleton LP, Sahin AA, Meric-Bernstam F, Kuerer HM, Feig BW, et al. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005;103(8):1581 -6. https://doi.org/10.1002/cncr.20934.
  266. Pugliese MS, Beatty JD, Tickman RJ, Allison KH, Atwood MK, Szymonifka J, et al. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories. Ann Surg Oncol. 2009;16(1 ):113-20. https://doi. org/10.1245/s10434-008-0121 -x; Epub 2008 Oct 23.
  267. Kogure K, David NJ, Yamanouchi U, Choromokos E. Infrared absorption angiography of the fundus circulation. Arch Ophthalmol. 1970;83(2):209 -14. https://doi.org/10.1001 /archo pht.1970.00990030211015.
  268. Elite system Spy. Elite system SPY: kit instructions for use. Branchburg, NJ: LifeCell corp; 2011.
  269. Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sentinel lymph node biopsy using indo- cyanine green fluorescence in early-stage breast cancer: a meta-analysis. Int J Clin Oncol. 2017;22(1):11-7. https://doi.org/10.1007/s10147-016-1064-z; Epub 2016 Nov 19.
  270. Zada A, Peek MC, Ahmed M, Anninga B, Baker R, Kusakabe M, et al. Meta-analysis of sentinel lymph node biopsy in breast cancer using the magnetic technique. Br J Surg. 2016;103(11 ):1409-19. https://doi.org/10.1002/bjs.10283; Epub 2016 Sep 9.
  271. Douek M, Klaase J, Monypenny I, Kothari A, Zechmeister K, Brown D, et al. Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG multicentre trial. Ann Surg Oncol. 2014;21 (4):1237-45. https://doi.org/10.1245/s10434-013-3379-6; Epub 2013 Dec 10.
  272. Thill M, Kurylcio A, Welter R, van Haasteren V, Grosse B, Berclaz G, et al. The central-European SentiMag study: sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. Breast. 2014;23(2):175-9. https://doi.org/10.1016/j.breast.2014.01.004; Epub 2014 Jan 29.
  273. Shiozawa M, Lefor AT, Hozumi Y, Kurihara K, Sata N, Yasuda Y, et al. Sentinel lymph node biopsy in patients with breast cancer using superparamagnetic iron oxide and a magnetometer. Breast Cancer. 2013;20(3):223-9. https://doi.org/10.1007/s12282-011 -0327-9; Epub 2012 Jan 13.
  274. Rubio IT, Diaz-Botero S, Esgueva A, Rodriguez R, Cortadellas T, Cordoba O, Espinosa-Bravo M. The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identi- fying the sentinel lymph node in breast cancer. Eur J Surg Oncol. 2015;41(1 ):46-51. https:// doi.org/10.1016/j.ejso.2014.11.006; Epub 2014 Nov 15.
  275. Pinero-Madrona A, Torro-Richart JA, de Leon-Carrillo JM, de Castro-Parga G, Navarro-Cecilia J, Dominguez-Cunchillos F, et al. Grupo de Estudios Senologicos de la Sociedad Espanola de Patologia Mamaria (SESPM). Superparamagnetic iron oxide as a tracer for sen- tinel node biopsy in breast cancer: A comparative non-inferiority study. Eur J Surg Oncol. 2015;41 (8):991 -7. https://doi.org/10.1016/j.ejso.2015.04.017; Epub 2015 May 12.
  276. Houpeau J.L., Chauvet M.P., Guillemin F., Bendavid-Athias C, Charitansky H, Kramar A, et al. Sentinel lymph node identification using superparamagnetic iron oxide particles versus radio- isotope: the French Sentimag feasibility trial. J Surg Oncol. 2016;113(5):501 -7. https://doi. org/10.1002/jso.24164; Epub 2016 Jan 12.
  277. Ghilli M, Carretta E, Di Filippo F, Battaglia C, Fustaino L, Galanou I, et al. The superparamag- netic iron oxide tracer: a valid alternative in sentinel node biopsy for breast cancer treatment. Eur J Cancer Care (Engl). 2017;26(4) https://doi.org/10.1111/ecc.12385; Epub 2015 Sep 14.
  278. Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol. 2014;15(8):e351 -62. https://doi.org/10.1016/ S1470-2045(13)70590-4.
  279. Karakatsanis A, Christiansen PM, Fischer L, Hedin C, Pistioli L, Sund M, et al. The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc(99) and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies. Breast Cancer Res Treat. 2016;157(2):281 -94. https://doi. org/10.1007/s10549-016-3809-9; Epub 2016 Apr 27.
  280. Teshome M, Wei C, Hunt KK, Thompson A, Rodriguez K, Mittendorf EA. Use of a magnetic tracer for sentinel lymph node detection in early-stage breast cancer patients: a meta-analysis. Ann Surg Oncol. 2016;23(5):1508-14. https://doi.org/10.1245/s10434-016-5135-1; Epub 2016 Feb 18.
  281. Alvarado MD, Mittendorf EA, Teshome M, Thompson AM, Bold RJ, Gittleman MA, et al. A non-inferiority trial comparing superparamagnetic iron oxide versus technetium-99m and blue dye in the detection of axillary sentinel nodes in patients with early-stage breast cancer. Ann Surg Oncol. 2019;26(11):3510-6. https://doi.org/10.1245/s10434-019-07577-4; Epub 2019 Jul 11.Erratum in: Ann Surg Oncol. 2020 Dec;27(Suppl 3):979.
  282. Hersi AF, Pistiolis L, Dussan Luberth C, Vikhe-Patil E, Nilsson F, Mohammed I, et al. Optimizing dose and timing in magnetic tracer techniques for sentinel lymph node detec- tion in early breast cancers: the prospective multicenter SentiDose trial. Cancers (Basel). 2021 ;13(4):693. https://doi.org/10.3390/cancers13040693.
  283. Taruno K, Kurita T, Kuwahata A, Yanagihara K, Enokido K, Katayose Y, et al. Multicenter clinical trial on sentinel lymph node biopsy using superparamagnetic iron oxide nanoparti- cles and a novel handheld magnetic probe. J Surg Oncol. 2019;120(8):1391 -6. https://doi. org/10.1002/jso.25747; Epub 2019 Oct 30.
  284. Pouw JJ, Ahmed M, Anninga B, Schuurman K, Pinder SE, Van Hemelrijck M, et al. Comparison of three magnetic nanoparticle tracers for sentinel lymph node biopsy in an in vivo porcine model. Int J Nanomedicine. 2015;10:1235-43. https://doi.org/10.2147/IJN.S76962.
  285. Rubio IT, Rodriguez-Revuelto R, Espinosa-Bravo M, Siso C, Rivero J, Esgueva A. A random- ized study comparing different doses of superparamagnetic iron oxide tracer for sentinel lymph node biopsy in breast cancer: the SUNRISE study. Eur J Surg Oncol. 2020;46(12):2195-201. https://doi.org/10.1016/j.ejso.2020.06.018; Epub 2020 Jun 18.
  286. Peek MCL, Saeki K, Ohashi K, Chikaki S, Baker R, Nakagawa T, et al. Optimization of SPIO injection for sentinel lymph node dissection in a rat model. Cancers (Basel). 2021;13(19):5031. https://doi.org/10.3390/cancers13195031.
  287. Huizing E, Anninga B, Young P, Monypenny I, Hall-Craggs M, Douek M. Analysis of void artefacts in post-operative breast MRI due to residual SPIO after magnetic SLNB in SentiMAG trial participants. Eur J Surg Oncol. 2015;41:S18. https://doi.org/10.1016/j.ejso.2015.03.005.
  288. Gkegkes ID, Iavazzo C. Contrast enhanced ultrasound (CEU) using microbubbles for sentinel lymph node biopsy in breast cancer: a systematic review. Acta Chir Belg. 2015;115(3):212-8. https://doi.org/10.1080/00015458.2015.11681099.
  289. Tanis PJ, Nieweg OE, Valdes Olmos RA, et al. History of sentinel node and validation of the technique. Breast Cancer Res. 2001;3:109-12.
  290. Hellman S. Natural history of small breast cancers. J Clin Oncol. 1994;12:2229-34.
  291. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-7.
  292. Haagensen CD, Feind KR, Herter FP, Slanetz CA, Weinberg JA. The lymphatics in cancer. Philadelphia: WB Saunders Company; 1972.
  293. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335-9.
  294. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymph- adenectomy for breast cancer. Ann Surg. 1994;220:391-8.
  295. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer — a multicenter vali- dation study. N Engl J Med. 1998;339:941-6.
  296. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106(1):4-16.
  297. Goyal A, Newcombe RG, Chhabra A, Mansel RE, ALMANAC Trialists Group. Factors affecting failed localisation and falsenegative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99(2):203-8.
  298. Tanis PJ, Nieweg OE, Hart AA, Kroon BB. The illusion of the learning phase for lymphatic mapping. Ann Surg Oncol. 2002;9(2):142-7.
  299. Veronesi U, Paganelli G, Viale G, et al. randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546-53.
  300. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer. Ann Surg. 2010;251(4):595-600.
  301. Krag DN, Anderson SJ, Julian TB. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast can- cer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-33.
  302. Krag DN, Anderson SJ, Julian TB, et al. National Surgical Adjuvant Breast and Bowel Project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881 -8.
  303. Krag DN, Ashikaga T, Harlow SP, Skelly JM, Julian TB, Brown AM, Weaver DL, Wolmark N. National Surgical Adjuvant Breast and Bowel Project. Surgeon training, protocol compli- ance, and technical outcomes from breast cancer sentinel lymph node randomized trial. J Natl Cancer Inst. 2009;101 (19):1356 -62.
  304. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703-20.
  305. Wu Y, Mittendorf EA, Kelten C, et al. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. 2012;118:1507-14.
  306. Zavagno G, De Salvo GL, Scalco GIVOM, Trialists. A Randomized clinical trial on senti- nel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247(2):207-13.
  307. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599-609.
  308. Gill G, SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinellymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 2009;16(2):266-75.
  309. Wetzig N, Gill PG, Espinoza D, et al. Sentinel-lymph-node-based management or routine axillary clearance? Five-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial: assessment and incidence of true lymphedema. Ann Surg Oncol. 2017;24(4):1064-70.
  310. Reynolds HM, Walker CG, Dunbar PR, et al. Functional anatomy of the lymphatics draining the skin: a detailed statistical analysis. J Anat. 2010;216(3):344-55. https://doi. org/10.1111/j.1469-7580.2009.01183.
  311. Halsted WS. I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46(1 ):1 -19.
  312. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial com- paring radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567-75. https://doi.org/10.1056/NEJMoa020128.
  313. Bonadonna G, Brusamolino E, Valagussa P, et al. Combined chemotherapy as adjuvant treat- ment in operable breast cancer. N Engl J Med. 1976;294:405-10.
  314. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82:1539-45.
  315. (TNM) National Comprehensive Cancer Network. Invasive breast cancer (Version 6.2020). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 12 Nov 2020.
  316. Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541 -57. https://doi.org/10.1093/ annonc/mdz235.
  317. Bates’ guide to physical examination and history taking. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009.
  318. Bromberg M. Assessment of lymphadenopathy. In: BMJ best practice; 2017. https://bestprac-tice.bmj.com/topics/en-gb/838.
  319. Rosenberg S. Lymph node exam findings stanford.edu. https://stanfordmedicine25.stanford. edu/the25/lymph.html.
  320. Lanng C, Hoffmann J, Galatius H, et al. Assessment of clinical palpation of the axilla as a criterion for performing the sentinel node procedure in breast cancer. Eur J Surg Oncol. 2007;33(3):281-4. https://doi.org/10.1016/j.ejso.2006.09.032; Epub 2006 Nov 3.
  321. Majid S, Bendahl PO, Huss L, et al. Validation of the Skane University Hospital nomogram for the preoperative prediction of a disease-free axilla in patients with breast cancer. BJS Open. 2021;5(3):zrab027. https://doi.org/10.1093/bjsopen/zrab027.
  322. de Freitas R, Costa MV, Schneider SV, et al. Accuracy of ultrasound and clinical examina- tion in the diagnosis of axillary lymph node metastases in breast cancer. Eur J Surg Oncol. 1991;17:240-4.
  323. Sauer T, Suciu V. The role of preoperative axillary lymph node fine needle aspiration in locoregional staging of breast cancer. Ann Pathol. 2012;32(6):e24-8, 410-4. English, French. https://doi.org/10.1016/j.annpat.2012.09.229.
  324. Specht MC, Fey JV, Borgen PI, et al. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J Am Coll Surg. 2005;200:10-4.
  325. Deurloo EE, Tanis PJ, Gilhuijs KG, et al. Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer. 2003;39(8):1068-73. https://doi.org/10.1016/s0959-8049(02)00748-7.
  326. Dialani V, James DF, Slanetz PJ. A practical approach to imaging the axilla. Insights Imaging. 2015;6(2):217-29. https://doi.org/10.1007/s13244-014-0367-824.
  327. Net JM, Mirpuri TM, Plaza MJ, et al. Resident and fellow education feature: US evaluation of axillary lymph nodes. Radiographics. 2014;34(7):1817-8. https://doi.org/10.1148/ rg.347140081.
  328. Britton PD, Goud A, Godward S, et al. Use of ultrasound-guided axillary node core biopsy in staging of early breast cancer. Eur Radiol. 2009;19:561-9.
  329. Sencha AN, et al. Breast ultrasound. Berlin: Springer-Verlag; 2013. https://doi. org/10.1007/978-3-642-36502-7_10.
  330. Alvarez S, Anorbe E, Alcorta P, et al. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol. 2006;186:1342-8.
  331. Bruneton JN, Caramella E, Hery M, et al. Axillary lymph node metastases in breast cancer: preoperative detection with US. Radiology. 1986;158:325-6.
  332. Tate JJ, Lewis V, Archer T, et al. Ultrasound detection of axillary lymph node metastases in breast cancer. Eur J Surg Oncol. 1989;15:139-41.
  333. Vaidya JS, Vyas JJ, Thakur MH, et al. Role of ultrasonography to detect axillary node involvement in operable breast cancer. Eur J Surg Oncol. 1996;22:140-3.
  334. Mustonen P, Farin P, Kosunen O. Ultrasonographic detection of metastatic axillary lymph nodes in breast cancer. Ann Chir Gynaecol. 1990;79:15-8.
  335. Lam WW, Yang WT, Chan YL, et al. Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography. Eur J Nucl Med. 1996;23:498-503.
  336. Yang WT, Ahuja A, Tang A, et al. High resolution sonographic detection of axillary lymph node metastases in breast cancer. J Ultrasound Med. 1996;16:241-6; erratum in: J Ultrasound Med 1996; 15:644.
  337. Verbanck J, Vandewiele I, De Winter H, et al. Value of axillary ultrasonography and sono- graphically guided needle biopsy of axillary nodes: a prospective study in 144 consecutive patients. J Clin Ultrasound. 1997;25:53-6.
  338. Bonnema J, van Geel AN, van Ooijen B, et al. Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method. World J Surg. 1997;21:270-4.
  339. Yang WT, Metreweli C. Colour Doppler flow in normal axillary lymph nodes. Br J Radiol. 1998;71:381 -3.
  340. de Kanter AY, van Eijck CH, van Geel AN, et al. Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg. 1999;86:1459-62.
  341. Krishnamurthy S, Sneige N, Bedi DG, et al. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer. 2002;95:982-8.
  342. Kuenen-Boumeester V, Menke-Pluymers M, de Kanter AY, et al. Ultrasound-guided fine needle aspiration cytology of axillary lymph nodes in breast cancer patients: a preoperative staging procedure. Eur J Cancer. 2003;39:170-4.
  343. Sapino A, Cassoni P, Zanon E, et al. Ultrasonographically-guided fine-needle aspiration of axillary lymph nodes: role in breast cancer management. Br J Cancer. 2003;88:702-6.
  344. Damera A, Evans AJ, Cornford EJ, et al. Diagnosis of axillary nodal metastases by ultrasound- guided core biopsy in primary operable breast cancer. Br J Cancer. 2003;89:1310-3.
  345. Bedrosian I, Bedi D, Kuerer HM, et al. Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol. 2003;10:1025-30.
  346. Cho N, Moon WK, Han W, et al. Preoperative sonographic classification of axillary lymph nodes in patients with breast cancer: node-to-node correlation with surgical histology and sentinel node biopsy results. AJR Am J Roentgenol. 2009;193:1731-7.
  347. Chen MY, Gillanders WE. Staging of the axilla in breast cancer and the evolving role of axil- lary ultrasound. Breast Cancer (Dove Med Press). 2021;13:311-23. https://doi.org/10.2147/ BCTT.S273039.
  348. Tucker NS, Cyr AE, Ademuyiwa FO, et al. Axillary ultrasound accurately excludes clini- cally significant lymph node disease in patients with early stage breast cancer. Ann Surg. 2015;264:1098.
  349. Johnson S, Brown S, Porter G, et al. Staging primary breast cancer. Are there tumour pathological features that correlate with a false-negative axillary ultrasound? Clin Radiol. 2011;66:497-9.
  350. Boughey JC, Ballman KV, Hunt KK, et al. Axillary ultrasound after neoadjuvant chemo- therapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015;33(30):3386-93. https://doi.org/10.1200/JCO.2014.57.840146.
  351. Boughey JC, Suman VJ, Mittendorf EA, et al. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1 -2) who receive neoadjuvant chemotherapy—results from the ACOSOG Z1071 trial (abstract). Cancer Res. 2012;72:S2-1.
  352. Hieken TJ, Boughey JC, Jones KN, et al. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann Surg Oncol. 2013;20(10):3199-204. https://doi.org/10.1245/s10434-013-3118-z.
  353. Di Micco R, Zuber V, Fiacco E, et al. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: time trend, imaging staging power and nodal down-staging according to molecular subtype. Eur J Surg Oncol. 2019;45(6):969-75. https://doi. org/10.1016/j.ejso.2019.01.21948.
  354. Peppe A, Wilson R, Pope R, et al. The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACt). Breast. 2017;35:104e8.
  355. Omoto K, Hozumi Y, Omoto Y, et al. Sentinel node detection in breast cancer using contrast- enhanced sonography with 25% albumin —initial clinical experience. J Clin Ultrasound. 2006;34(7):317-26. https://doi.org/10.1002/jcu.20241.
  356. Xu HX. Contrast-enhanced ultrasound: the evolving applications. World J Radiol.2009;1:15-24.
  357. Xie F, Zhang D, Cheng L, et al. Intradermal microbubbles and contrast-enhanced ultrasound (CEUS) is a feasible approach for sentinel lymph node identification in early-stage breast cancer. World J Surg Oncol. 2015;13:319. https://doi.org/10.1186/s12957-015-0736-x.
  358. Dellaportas D, Koureas A, Contis J, et al. Contrast-enhanced color Doppler ultrasonography for preoperative evaluation of sentinel lymph node in breast cancer patients. Breast Care (Basel). 2015;10(5):331 -5. https://doi.org/10.1159/000436958; Epub 2015 Jul 10.
  359. Zhong J, Sun DS, Wei W, et al. Contrast-enhanced ultrasound-guided fine-needle aspira- tion for sentinel lymph node biopsy in early-stage breast cancer. Ultrasound Med Biol. 2018;44(7):1371-8. https://doi.org/10.1016/j.ultrasmedbio.2018.03.005; Epub 2018 Apr 6.
  360. Marti JL, Ayo D, Levine P, et al. Nonimage-guided fine needle aspiration biopsy of palpable axillary lymph nodes in breast cancer patients. Breast J. 2012;18:3-7.
  361. Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients: a study of 115 cases with cytologic-histologic correlation. Cancer. 2008;114:89-93.
  362. O'Malley FP, Pinder SE, Mulligan AM. Breast pathology E-Book: a volume in the series: Foundations in diagnostic pathology. Edinburgh: Churchill Livingstone; 2011.
  363. Park SH, Kim MJ, Park BW, et al. Impact of preoperative ultrasonography and fine-needle aspiration of axillary lymph nodes on surgical management of primary breast cancer. Ann Surg Oncol. 2011 ;18:738-44.
  364. van Rijk MC, Deurloo EE, Nieweg OE, et al. Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol. 2006;13:31 -5.
  365. Koelliker SL, Chung MA, Mainiero MB, et al. Axillary lymph nodes: US-guided fine-needle aspiration for initial staging of breast cancer-correlation with primary tumor size. Radiology. 2008;246:81 -9.
  366. Baruah BP, Goyal A, Young P, et al. Axillary node staging by ultrasonography and fine-needle aspiration cytology in patients with breast cancer. Br J Surg. 2010;97:680-3.
  367. Houssami N, Ciatto S, Turner RM, et al. Preoperative US-guided needle biopsy of axillary nodes in invasive breast cancer. Meta-analysis of its accuracy and utility in staging the axilla. Ann Surg. 2011 ;254:243-51.
  368. Jain A, Haisfield-Wolfe ME, Lange J, et al. The role of ultrasound-guided fine needle aspira- tion of axillary nodes in the staging of breast cancer. Ann Surg Oncol. 2008;15:462-71.
  369. Rao R, Lilley L, Andrews V, et al. Axillary staging by percutaneous biopsy: sensitivity of fine-needle aspiration versus core needle biopsy. Ann Surg Oncol. 2009;16:1170-5.
  370. Balasubramanian I, Fleming CA, Corrigan MA, et al. Meta-analysis of the diagnostic accu- racy of ultrasound-guided fine-needle aspiration and core needle biopsy in diagnosing axil- lary lymph node metastasis. Br J Surg. 2018;105(10):1244-53. https://doi.org/10.1002/ bjs.10920; Epub 2018 Jul 4.
  371. Cangiarella J, Simsir A, Tabbara SO. Breast cytohistology. Cambridge: Cambridge University Press; 2013.
  372. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axil- lary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918-26. https://doi.org/10.1001/jama.2017.11470.
  373. van Nijnatten TJA, Ploumen EH, Schipper RJ, et al. Routine use of standard breast MRI compared to axillary ultrasound for differentiating between no, limited and advanced axillary nodal disease in newly diagnosed breast cancer patients. Eur J Radiol. 2016;85(12):2288-94.
  374. Arslan G, et al. Diagnostic accuracy of metastatic axillary lymph nodes in breast MRI. Springerplus. 2016;5(1):735. https://doi.org/10.1186/s40064-016-2419-7.
  375. Kvistad KA, Rydland J, Smethurst HB, et al. Axillary lymph node metastases in breast cancer: preoperative detection with dynamic contrast-enhanced MRI. Eur Radiol. 2000;10(9):1464-71. https://doi.org/10.1007/s003300000370.
  376. Chang JM, Leung JWT, Moy L, et al. Axillary nodal evaluation in breast cancer: state of the art. Radiology. 2020;295(3):500-15. https://doi.org/10.1148/radiol.2020192534; Epub 2020 Apr 21.
  377. Cooper KL, Meng Y, Harnan S, et al. Positron emission tomography (PET) and magnetic res- onance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2011 ;15(4):iii - v, 1-134. https://doi.org/10.3310/hta15040.
  378. Ramirez SI, Scholle M, Buckmaster J, et al. Assessment of the accuracy of ultrasound com- pared to magnetic resonance imaging in the ability to detect metastatic breast cancer to the axilla (abstract). Surg Tech Dev. 2012;2. https://doi.org/10.4081/std.2012.e4.
  379. Javid S, Segara D, Lotfi P, et al. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy? Ann Surg Oncol. 2010;17:1841 -6.
  380. Williams A, Litton KJ, Borley A, et al. Imaging the breast following neoadjuvant chemotherapy: does improvement of imaging findings in the axilla predict pathological response in the breast? Breast Cancer Res. 2012;14(Suppl 1):P30.
  381. Kuijs VJL, Moossdorff M, Schipper RJ, et al. The role of MRI in axillary lymph node imag- ing in breast cancer patients: a systematic review. Insights Imaging. 2015;6:203-15. https:// doi.org/10.1007/s13244-015-0404-2.
  382. Koolen BB, Valdes Olmos RA, Wesseling J, et al. Early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implica- tions for surgical management of the axilla. Ann Surg Oncol. 2013;20(7):2227-35. https:// doi.org/10.1245/s10434-013-2902-0; Epub 2013 Mar 1.
  383. NCCN Guidelines Version 2.2022 Breast Cancer. www.nccn.org.
  384. Wallis MG, Kilburn-Toppin F, Taylor-Phillips S. Does preoperative axillary staging lead to overtreatment of women with screen-detected breast cancer? Clin Radiol. 2018;73(5):467-72.
  385. Verheuvel NC, van den Hoven I, Ooms HW, et al. The role of ultrasound-guided lymph node biopsy in axillary staging of invasive breast cancer in the post-ACOSOG Z0011 trial era. Ann Surg Oncol. 2015;22(2):409 -15. https://doi.org/10.1245/s10434-014-4071 -1.
  386. Caudle AS, Kuerer HM, Le-petross HT, et al. Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol. 2014;21(11):3440-7. https://doi.org/10.1245/ s10434-014-3813-4.
  387. Joh JE, Han G, Kiluk JV, et al. Indications for axillary ultrasound use in breast cancer patients. Clin Breast Cancer. 2012;12(6):433-7. https://doi.org/10.1016/j.clbc.2012.09.009.
  388. Boland MR, Prichard RS, Daskalova I, et al. Axillary nodal burden in primary breast cancer patients with positive preoperative ultrasound guided fine needle aspiration cytology: man- agement in the era of ACOSOG Z0011. Eur J Surg Oncol. 2015;41(4):559-65.
  389. Reyna C, Kiluk JV, Frelick A, et al. Impact of axillary ultrasound (AUS) on axillary dissection in breast conserving surgery (BCS). J Surg Oncol. 2015;111:813e8.
  390. AIOM. Associazione Italiana di Oncologia Medica. Linee guida NEOPLASIE DELLA MAMMELLA. Edizione 2020. https://www.aiom.it/.
  391. Brackstone M, Baldassarre FG, Perera FE, et al. Management of the Axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO guideline. J Clin Oncol. 2021;39(27):3056-82. https://doi.org/10.1200/JCO.21.00934; Epub 2021 Jul 19.
  392. Breast cancer. Dutch Guideline, version 2.0. https://www.oncoline.nl/uploaded/docs/mam-macarcinoom/Dutch%20Breast%20Cancer%20Guideline%202012.pdf.
  393. Early and locally advanced breast cancer: diagnosis and management. NICE guideline. Published: 18 July 2018. www.nice.org.uk/guidance/ng101.
  394. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with con- ventional axillary-lymph-node dissection in clinically node-negative patients with breast can- cer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-33. https://doi.org/10.1016/S1470-2045(10)70207-2.
  395. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303-10. https://doi.org/10.1016/S1470-2045(14)70460-7; Epub 2014 Oct 15.
  396. Savolt A, Peley G, Polgar C, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla -surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672-9. https://doi.org/10.1016/j.ejso.2016.12.011; Epub 2017 Jan 16.
  397. Sola M, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013;20(1):120-7. https:// doi.org/10.1245/s10434-012-2569-y; Epub 2012 Sep 7.
  398. Galimberti V, Cole BF, Viale G, et al. International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel- node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(10):1385-93. https://doi.org/10.1016/S1470-2045(18)30380-2; Epub 2018 Sep 5.
  399. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595-600.
  400. Classe JM, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173(2):343-52. https://doi.org/10.1007/ s10549-018-5004-7; Epub 2018 Oct 20.
  401. Hunt KK, Ballman KV, McCall LM, et al. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012;256:428-36.
  402. Nogi H, Uchida K, Mimoto R, et al. Long-term follow-up of node-negative breast cancer patients evaluated via sentinel node biopsy following neoadjuvant chemotherapy. Clin Breast Cancer. 2017;17:644. https://doi.org/10.1016/j.clbc.2017.05.002.
  403. Balachandran VP, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173-80. https://doi.org/10.1016/S1470-2045(14)71116-7.
  404. Hu X, Xue J, Peng S, et al. Preoperative nomogram for predicting sentinel lymph node metas- tasis risk in breast cancer: a potential application on omitting sentinel lymph node biopsy. Front Oncol. 2021;11:665240. https://doi.org/10.3389/fonc.2021.665240.
  405. Tran HT, Pack D, Mylander C, et al. Ultrasound-based nomogram identifies breast can- cer patients unlikely to harbor axillary metastasis: towards selective omission of senti- nel lymph node biopsy. Ann Surg Oncol. 2020;27(8):2679-86. https://doi.org/10.1245/ s10434-019-08164-3; Epub 2020 Feb 5.
  406. Wang L, Li J, Qiao J, et al. Establishment of a model for predicting sentinel lymph node metastasis in early breast cancer based on contrast-enhanced ultrasound and clinicopatho- logical features. Gland Surg. 2021 ;10(5):1701 -12. https://doi.org/10.21037/gs-21 -245.
  407. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast can- cer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609-18. https://doi.org/10.1016/S1470-2045(13)70166-9.
  408. Liedtke C, Kolberg HC, Kerschke L, et al. Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN) in patients with breast cancer converting from cN to ycN0 through primary systemic therapy (PST). Clin Exp Metastasis. 2018;35(8):777-83.
  409. van Timmeren JE, Cester D, Tanadini-Lang S, et al. Radiomics in medical imaging-"how- to” guide and critical reflection. Insights Imaging. 2020;11(1):91. https://doi.org/10.1186/ s13244-020-00887-2.
  410. Zhou WJ, Zhang YD, Kong WT, et al. Preoperative prediction of axillary lymph node metas- tasis in patients with breast cancer based on radiomics of gray-scale ultrasonography. Gland Surg. 2021 ;10(6):1989-2001. https://doi.org/10.21037/gs-21-315.
  411. Yu FH, Wang JX, Ye XH, et al. Ultrasound-based radiomics nomogram: a potential bio- marker to predict axillary lymph node metastasis in early-stage invasive breast cancer. Eur J Radiol. 2019;119:108658. https://doi.org/10.1016/j.ejrad.2019.108658; Epub 2019 Sep 7.
  412. Cyr AE, T ucker N, Ademuyiwa F, et al. Successful completion of the pilot phase of a ran- domized controlled trial comparing sentinel lymph node biopsy to no further axillary stag- ing in patients with clinical T1-T2 N0 breast cancer and normal axillary ultrasound. J Am Coll Surg. 2016;223(2):399-407. https://doi.org/10.1016/jjamcollsurg.2016.04.048; Epub 2016 May 20.
  413. Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: senti- nel node vs observation after axillary UltraSouND). Breast. 2012;21(5):678-81. https://doi. org/10.1016/j.breast.2012.06.013; Epub 2012 Jul 25.
  414. Hildebrandt G, Stachs A, Gerber B, et al. Central review of radiation therapy planning among patients with breastconserving surgery: results from a quality assurance process integrated into the INSEMA trial. Int J Radiat Oncol Biol Phys. 2020;107(4):683-93. https://doi. org/10.1016/j.ijrobp.2020.04.042; Epub 2020 May 11.
  415. van Roozendaal LM, Vane MLG, van Dalen T, et al. Clinically node negative breast can- cer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08). BMC Cancer. 2017;17(1):459. https://doi.org/10.1186/s12885-017-3443-x.
  416. Standring S. Gray’s anatomy: The anatomical basis of Clinical practice. Upper Extremity. 39th ed. Edinburgh: Elsevier. Р. 962.
  417. Jatoi I, Kaufmann M, Petit JY. Anatomy; chapter 2. In: Atlas of breast surgery. Berlin: Springer-Verlag; 2006. p. 7-15.
  418. Jatoi I, Kaufmann M, Petit JY. Surgery for breast carcinoma; chapter 6. In: Atlas of breast surgery. Berlin: Springer-Verlag; 2006. Р. 61 -84.
  419. Manasseh D-ME, Willey SC. Invasive carcinoma: mastectomy and staging the axilla. In: Spear SL, editor. Surgery of the breast, vol. 1.2nd ed. Philadelphia: Lippincott Williams & Wilkins. Р. 131 -7.
  420. Delay E. Breast reconstruction with an autologous latissimus musculocutaneous flap with and without immediate nipple reconstruction. In: Spear SL, editor. Surgery of the breast, vol. 1.2nd ed. Philadelphia: Lippincott Williams & Wilkins. Р. 631 -55.
  421. Uzmansel D, Kurtoglou Z, Kara A, Ozturk NC. Frequency, anatomical properties and innerva- tion of axillary arch and its relations to the brachial plexus in human fetuses. Surg Radiol Anat. 2010;32:859-63.
  422. Besana-Ciani I, Greenall MJ. Langer’s axillary arch: anatomy, embryological features and surgical implications. Surgeon. 2005;3(5):325-7.
  423. Natsis K, Vlasis K, Totlis T, Paraskevas G, Noussios G, Skandalakis P, Koebke J. Breast Cancer Res Treat. 2010;120:77-82.
  424. Daniels IR, Quersi della Rovere G. The axillary arch of Langer- the most common muscular variation in the axilla. Breast Cancer Res Treat. 2000;59:77-80.
  425. Pickren JW. Lymph node metastases in carcinoma of the female mammary gland. Bull Roswell Park Mem Inst. 1956;1:79.
  426. Grossman F. Ueber die axillaren lymphdrusen. Dissert. Berlin; 1896.
  427. Rotter J. Zur topographic des mammacarcinoms. Arch F Klin Chir. 1899;58:346.
  428. Egan RL, McSweeney MB. Intramammary lymph nodes. Cancer. 1983;51:1838.
  429. Berg JW. The significance of axillary node levels in the study of breast carcinoma. Cancer. 1955;8:776.
  430. Mansel RE, Khonji NI, Clarke D. History, present status and future of sentinel node biopsy in breast cancer: The Mary Beves Lecture. Acta Oncol. 2000;39(3):265-8. https://doi. org/10.1080/028418600750012998.
  431. Tanis PJ, Nieweg OE, Valdes Olmos RA, Th Rutgers EJ, Kroon BB. History of sentinel node and validation of the technique. Breast Cancer Res. 2001;3(2):109-12. https://doi.org/10.1186/ bcr281; Epub 2001 Jan 23.
  432. Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a “sentinel node” in cancer of the parotid. Cancer. 1960;13:77-8.
  433. Chiappa S, Uslenghi C, Bonadonna G, Marano P, Ravasi G. Combined testicular and foot lym- phangiography in testicular carcinomas. Surg Gynecol Obstet. 1966;123(1):10-4.
  434. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392-9. https://doi.org/10.1001/archsurg.1992.01420040034005.
  435. Morton DL, Wen DR, Cochran AJ. Pathophysiology of regional lymph node metastases in early melanoma studied by intraoperative mapping of the cutaneous lymphatics. Second inter- national conference on melanoma, 1989.
  436. Haagensen CD, Feind KR, Herter FP, Slanetz CA, Weinberg JA. The lymphatics in cancer. Philadelphia: WB Saunders; 1972.
  437. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymph- adenectomy for breast cancer. Ann Surg. 1994;220(3):391 -8; discussion 398-401. https://doi. org/10.1097/00000658-199409000-00015.
  438. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-48.
  439. Gonzalez A. Sentinel lymph node biopsy: past and present implications for the Management of Cutaneous Melanoma with nodal metastasis. Am J Clin Dermatol. 2018;19:24-30. https:// doi.org/10.1007/s40257-018-0379-0.
  440. Bland CS. The Halsted mastectomy: present illness and past history. West J Med.1981;134(6):549-55.
  441. Toesca A, Luini A, Veronesi P, Intra M, Gentilini O. Sentinel lymph node biopsy in early breast cancer: the experience of the European Institute of Oncology in special clinical scenarios. Breast Care (Basel). 2011 ;6(3):208-14. https://doi.org/10.1159/000329192.
  442. Giuliano AE. Mapping a pathway for axillary staging: a personal perspective on the current status of sentinel lymph node dissection for breast cancer. Arch Surg. 1999;134:195-9.
  443. Reintgen DS, Cruse CW, Wells KE, Berman CG, Fenske NA, Glass LF, Schroer K, Heller R, Ross MI, Lyman GH, Cox C, Rap-paport D, Seigler HF, Balch C, et al. The orderly progres- sion of melanoma nodal metastases. Ann Surg. 1994;220:759-67.
  444. Kapteijn BAE, Nieweg OE, Peterse JL, Rutgers EJT, Hart AAM, Van Dongen JA, Kroon BBR. Identification and biopsy of the sentinel lymph node in breast cancer. Eur J Surg Oncol. 1998;24:427-30.
  445. Kett K, Varga G, Lukacs L. Direct lymphography of the breast. Lymphology. 1970 Mar;3(1):2-12.
  446. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet. 1997;349:1864-7.
  447. O’Hea BJ, Hill ADK, El-Shirbiny AM, et al. Sentinel node biopsy in breast cancer; initial experience at Memorial Sloan-Kettering Cancer Centre. J Am Coll Surg. 1998;186:423-7.
  448. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP, American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703-20.
  449. Breast Cancer Professional Committee of Chinese Anti-cancer Association. Guidelines and specifications for the diagnosis and treatment of breast cancer of Chinese Anti-cancer Association (2019 edition). Chin J Cancer. 2019;29:609-79. https://doi.org/10.19401 /j. cnki.1007-3639.2019.08.009.
  450. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissec- tion in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-33.
  451. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011 ;305(6):569-75.
  452. Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE, American College of Surgeons Oncology Group. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657-63.
  453. Chatterjee A, Serniak N, Czerniecki BJ. Sentinel lymph node biopsy in breast cancer: a work in progress. Cancer J. 2015;21(1 ):7-10. https://doi.org/10.1097/PPO.0000000000000090.
  454. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251(4):595-600.
  455. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98(9):599 - 609.
  456. Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axil- lary dissection in patients with histologically confirmed nodal metastases? Results of a pro- spective study. Ann Surg Oncol. 2016;23:3467-74.
  457. Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel- lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609-18.
  458. Boughey JC, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455-61.
  459. Veronesi U., Cascinelli N., Mariani L., Greco M., Saccozzi R., Luini A. et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer // N. Engl. J. Med. 2002. Vol. 347, N 16. P. 1227-1232.
  460. Voogd A.C., Nielsen M., Peterse J.L., Blichert-Toft M., Bartelink H., Overgaard M. et al. Differences in risk factors for local and distant recurrence after breastconserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials // J. Clin. Oncol. 2001. Vol. 19, N 6. P. 1688-1697.
  461. Kroman N., Holtveg H., Wohlfahrt J., Jensen M.B., Mouridsen H.T., Blichert-Toft M. et al. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma // Cancer. 2004. Vol. 100, N 4. P. 688-693.
  462. Bantema-Joppe E.J., de Munck L., Visser O., Willemse P.H., Langendijk J.A., Siesling S. et al. Early-stage young breast cancer patients: impact of local treatment on survival // Int. J. Radiat. Oncol. Biol. Phys. 2011. Vol. 81, N 4. P. e553-e559.
  463. van der Sangen M.J., van de Wiel EM., Poortmans P.M., Tjan-Heijnen V.C., Nieuwenhuijzen G.A., Roumen R.M. et al. Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Longterm results of a population-based cohort of 1,451 patients aged < 40 years // Breast Cancer Res. Treat. 2011. Vol. 127, N 1. P. 207-215.
  464. Mahmood U., Morris C., Neuner G., Koshy M., Kesmodel S., Buras R. et al. Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast cancer // Int. J. Radiat. Oncol. Biol. Phys. 2012. Vol. 83, N 5. P. 1387-1393.
  465. Jeon Y.W., Choi J.E., Park H.K., Kim K.S., Lee J.Y., Suh YJ. Impact of local surgical treatment on survival in young women with T1 breast cancer: long-term results of a population-based cohort // Breast Cancer Res. Treat. 2013. Vol. 138, N 2. P. 475-484.
  466. Vila J., Gandini S., Gentilini O. Overall survival according to type of surgery in young (<40 years) early breast cancer patients: a systematic meta-analysis comparing breast-conserving surgery versus mastectomy // Breast. 2015. Vol. 24, N3. P. 175-181.
  467. Arriagada R., Le M.G., Guinebretiere J.M., Dunant A., Rochard E, Tursz T. Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients // Ann. Oncol. 2003. Vol. 14, N 11. P. 1617-1622.
  468. Blichert-Toft M., Nielsen M., During M., Moller S„ Rank E, Overgaard M. et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol // Acta Oncol. 2008. Vol. 47, N 4. P. 672-681.
  469. Fisher B., Anderson S., Bryant J., Margolese R.G., Deutsch M., Fisher E.R. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer//N. Engl. J. Med. 2002. Vol. 347, N 16. P. 1233-1241.
  470. Poggi M.M., Danforth D.N., Sciuto L.C., Smith S.L., Steinberg S.M., Liewehr DJ. et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial // Cancer. 2003. Vol. 98, N 4. P. 697-702.
  471. van Dongen J.A., Voogd A.C., Fentiman I.S., Legrand C., Sylvester R.J., Tong D. et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial //J. Natl Cancer Inst. 2000. Vol. 92, N 14. P. 1143-1150.
  472. Cao J.Q., Olson R.A., Tyldesley S.K. Comparison of recurrence and survival rates after breast-conserving therapy and mastectomy in young women with breast cancer // Curr. Oncol. 2013. Vol. 20, N 6. P. e593-e601.
  473. Ye J.C., Yan W., Christos P.J., Nori D., Ravi A. Equivalent survival with mastectomy or breast-conserving surgery plus radiation in young women aged <40 years with early-stage breast cancer: a National Registry-based Stage-by-Stage Comparison // Clin. Breast Cancer. 2015. Vol. 15, N 5. P. 390-397.
  474. Fodor J., Mozsa Е., Zaka Z., Polgar C., Major T. Local relapse in young (< or = 40 years) women with breast cancer after mastectomy or breast conserving surgery: 15-year results // Magy. Onkol. 2005. Vol. 49, N 3. P. 203, 205-208.
  475. Bantema-Joppe EJ., van den Heuvel E.R., de Munck L., de Bock G.H., Smit W.G., Timmer P.R. et al. Impact of primary local treatment on the development of distant metastases or death through locoregional recurrence in young breast cancer patients // Breast Cancer Res Treat. 2013. Vol. 140, N 3. P. 577-585.
  476. Beadle B.M., Woodward W.A., Tucker S.L., Outlaw E.D., Allen P.K., Oh J.L. et al. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach // Int. J. Radiat. Oncol. Biol. Phys. 2009. Vol. 73, N 3. P. 734-744.
  477. Maishman T, Cutress R.I., Hernandez A., Gerty S., Copson E.R., Durcan L. et al. Local recurrence and breast oncological surgery in young women with breast cancer: the POSH Observational Cohort Study // Ann. Surg. 2017. Vol. 266. P. 165-172.
  478. Quan M.L., Paszat L.F., Fernandes K.A., Sutradhar R., McCready D.R., Rakovitch E. et al. The effect of surgery type on survival and recurrence in very young women with breast cancer //J. Surg. Oncol. 2017. Vol. 115, N 2. P. 122-130.
  479. Gentilini O., Botteri E., Rotmensz N.. Toesca A., De Oliveira H., Sangalli C. et al. Breast-conserving surgery in 201 very young patients (<35 years) // Breast. 2010. Vol. 19, N 1. P. 55-58.
  480. Aalders K.C., Postma E.L., Strobbe L.J., van der Heiden-van der Loo M., Sonke G.S., Boersma LJ. et al. Contemporary locoregional recurrence rates in young patients with early-stage breast cancer // J. Clin. Oncol. 2016. Vol. 34, N 18. P. 2107-2114.
  481. Botteri E., Veronesi P, Vila J., Rotmensz N, Galimberti V, Thomazini M.V. et al. Improved prognosis of young patients with breast cancer undergoing breastconserving surgery // Br. J. Surg. 2017. Vol. 104. P. 1802-1810.
  482. Bartelink H., Horiot J.C., Poortmans P, Struikmans H., Van den Bogaert W., Barillot I. et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation // N. Engl. J. Med. 2001. Vol. 345, N 19. P. 1378-1387.
  483. Fisher E.R., Anderson S., Tan-Chiu E., Fisher B., Eaton L., Wolmark N. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06 // Cancer. 2001. Vol. 91, N 8. Suppl. P. 1679-1687.
  484. Paluch-Shimon S., Pagani O., Partridge A.H., Bar-Meir E., Fallowfield L., Fenlon D. et al. Second international consensus guidelines for breast cancer in young women (BCY2) // Breast. 2016. Vol. 26. P. 87-99.
  485. Fisher B., Jeong J.H., Anderson S., Bryant J., Fisher E.R., Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation // N. Engl. J. Med. 2002. Vol. 347, N 8. P. 567 575.
  486. Miles R.C., Gullerud R.E., Lohse C.M., Jakub J.W, Degnim A.C., Boughey J.C. Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age // Ann. Surg. Oncol. 2012. Vol. 19, N 4. P. 1153-1159.
  487. Partridge A.H., Pagani O., Abulkhair O., Aebi S., Amant E, Azim H.A. et al. First international consensus guidelines for breast cancer in young women (BCY1) // Breast. 2014. Vol. 23, N 3. P. 209-220.
  488. O’Connell R.L., DiMicco R., Khabra K., O’Flynn E.A., deSouza N., Roche N. et al. Initial experience of the BREAST-Q breast-conserving therapy module // Breast Cancer Res. Treat. 2016. Vol. 160. P. 79-89.
  489. King T.A. Selecting local therapy in the young breast cancer patient //J. Surg. Oncol. 2011. Vol. 103, N 4. P. 330-336.
  490. Silverstein M.J., Savalia N., Khan S., Ryan J. Extreme oncoplasty: breast conservation for patients who need mastectomy // Breast J. 2015. Vol. 21, N 1. P. 52-59.
  491. Silverstein MJ. Radical mastectomy to radical conservation (extreme oncoplasty): a revolutionary change //J. Am. Coll. Surg. 2016. Vol. 222, N 1. P. 1-9.
  492. Paluch-Shimon S., Pagani O., Partridge A.H., Abulkhair O., Cardoso MJ., Dent R.A. et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) // Breast. 2017. Vol. 35. P. 203-217.
  493. National Mastectomy and Breast Reconstruction Audit. 2011.
  494. Garcia-Etienne C.A., Barile M., Gentilini O.D., Botteri E., Rotmensz N., Sagona A. et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? // Ann. Surg. Oncol. 2009. Vol. 16, N 12. P. 3380-3387.
  495. Domchek S.M., Friebel T.M., Singer C.F., Evans D.G., Lynch H.T., Isaacs C. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality //JAMA. 2010. Vol. 304, N 9. P. 967-975.
  496. Bernstein J.L., Thomas D.C., Shore R.E., Robson M., Boice J.D., Stovall M. et al. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report // Eur. J. Cancer. 2013. Vol. 49, N 14. P. 2979-2985.
  497. Pierce L.J., Levin A.M., Rebbeck T.R., Ben-David M.A., Friedman E., Solin LJ. et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCAl/2-associated stage I/II breast cancer //J. Clin. Oncol. 2006. Vol. 24, N 16. P. 2437-2443.
  498. Tuttle T.M., Barrio A.V, Klimberg V.S., Giuliano A.E., Chavez-MacGregor M., Buum H.A. et al. Guidelines for guidelines: an assessment of the American Society of breast surgeons contralateral prophylactic mastectomy consensus statement // Ann. Surg. Oncol. 2017. Vol. 24, N 1. P. 1-2.
  499. Yao K., Stewart A.K., Winchester D.J., Winchester D.P. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007 // Ann. Surg. Oncol. 2010. Vol. 17, N 10. P. 2554-2562.
  500. Arrington A.K., Jarosek S.L., Virnig B.A., Habermann E.B., Tuttle T.M. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer // Ann. Surg. Oncol. 2009. Vol. 16, N 10 P. 2697-2704.
  501. King Т.А., Sakr R., Patil S., Gurevich I., Stempel M., Sampson M. et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy //J. Clin. Oncol. 2011. Vol. 29, N 16. P. 2158-2164.
  502. Jones N.B., Wilson J., Kotur L., Stephens J., Farrar W.B., Agnese D.M. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution // Ann. Surg. Oncol. 2009. Vol. 16, N 10. P. 2691-2696.
  503. Kurian A.W., Lichtensztajn D.Y., Keegan Т.Н., Nelson D.O., Clarke C.A., Gomez S.L. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011 // JAMA. 2014. Vol. 312, N9. P. 902-914.
  504. Rosenberg S.M., Tracy M.S., Meyer M.E., Sepucha K., Gelber S„ Hirshfield-BartekJ. et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey // Ann. Intern. Med. 2013. Vol. 159, N 6. P. 373-381.
  505. Cardoso E, Loibl S., Pagani O., Graziottin A., Panizza P, Martincich L. et al. The European Society of breast cancer specialists recommendations for the management of young women with breast cancer // Eur. J. Cancer. 2012. Vol. 48, N 18. P. 3355-3377.
  506. Rosenberg S.M., Partridge A.H. Management of breast cancer in very young women // Breast. 2015. Vol. 24, suppl. 2. P. S154-S158.
  507. Moran BJ., Yano H., Al Zahir N., Farquharson M. Conflicting priorities in surgical intervention for cancer in pregnancy // Lancet Oncol. 2007. Vol. 8, N 6. P. 536-544.
  508. Amant E, Deckers S., Van Calsteren K., Loibl S., Halaska M., Brepoels L. et al. Breast cancer in pregnancy: recommendations of an international consensus meeting // Eur. J. Cancer. 2010. Vol. 46, N 18. P. 3158-3168.
  509. Lohsiriwat V, Peccatori F.A., Martella S., Azim H.A., Sarno M.A., Galimberti V. et al. Immediate breast reconstruction with expander in pregnant breast cancer patients // Breast. 2013. Vol. 22, N 5. P. 657-660.
  510. Toesca A., Gentilini O., Peccatori E, Azim H.A., Amant F. Locoregional treatment of breast cancer during pregnancy // Gynecol. Surg. 2014. Vol. 11, N 4. P. 279-284.
  511. Gentilini O., Cremonesi M., Toesca A., Colombo N., Peccatori E, Sironi R. et al. Sentinel lymph node biopsy in pregnant patients with breast cancer // Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37, N 1. P. 78-83.
  512. Loibl S., Schmidt A., Gentilini O., Kaufman B., Kuhl C., Denkert C. et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients //JAMA Oncol. 2015. Vol. 1, N 8. P. 1145-1153.
  513. Aebi S., Gelber S., Anderson S.J., Lang L, Robidoux A., Martin M. et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial // Lancet Oncol. 2014. Vol. 15, N 2. P. 156-163.
  514. Wapnir I.L., Gelber S., Anderson S.J., Mamounas E.P, Robidoux A., Martin M. et al. Poor prognosis after second locoregional recurrences in the CALOR Trial // Ann. Surg. Oncol. 2017. Vol. 24, N 2. P. 398-406.
  515. Bland KI, Copeland III EM, Klimberg SV. History of the therapy of breast cancer. The Breast (Fifth Edition) 2018. Pages 1 -19. e3.
  516. https://www.news-medical.net/health/History-of-Breast-Cancer.aspx.
  517. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181-7.
  518. Sakorafas GH, Safioleas M. Breast cancer surgery: an historical narrative. Part II. 18th and 19th centuries.
  519. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335-9.
  520. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymph-adenectomy for breast cancer. Ann Surg. 1994;220(3):391.
  521. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guide- line recommendations for sentinel lymph node biopsy in early-stage Breast cancer. J Clin Oncol. 2005;23(7):703-20.
  522. Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, Duffy SW. Morbidity after sentinel lymph node biopsy in primary Breast cancer: results from a ran- domized controlled trial. J Clin Oncol. 2005;23:4312-21.
  523. Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymph- adenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18:2553-9.
  524. Brorson H, Ohlin K, Olsson G, Karlsson MK. Breast cancer-related chronic arm lymphedema is associated with excess adipose and muscle tissue. Lymphat Res Biol. 2009;7(1):3-10.
  525. Greene A, Goss J. Diagnosis and staging of lymphedema. Semin Plast Surg. 2018;32(1):12-6.
  526. The diagnosis and treatment of peripheral lymphedema: 2020 Consensus Document of the International Society of Lymphology.
  527. McLaughlin SA, Wright MJ, Morris KT, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ. Prevalence of lymphedema in women with Breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. J Clin Oncol. 2008;26:5220-6.
  528. Mansel R, et al. Randomised multicentre trial of sentinel node biopsy versus standard axillary treatment in operable Breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599-609.
  529. Stewart FW. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in Elephantiasis chirurgica. Cancer. 1948;1:64-81.
  530. Mesli SN, Ghouali AK, Benamara F, Taleb FA, Tahraoui H, Abi-Ayad C. Stewart-Treves syndrome involving chronic lymphedema after mastectomy of breast cancer. Case Rep Surg. 2017;2017:4056459.
  531. Ivens D, Hoe AL, Podd TJ, et al. Assessment of morbidity from complete axillary dissection. Br J Cancer. 1992;66:136-8.
  532. Henry BM, Graves MJ, P^kala JR, Sanna B, Hsieh WC, Tubbs RS, Walocha JA, Tomaszewski KA. Origin, branching, and communications of the intercostobrachial nerve: a meta-analysis with implications for mastectomy and axillary lymph node dissection in breast cancer. Cureus. 2017;9(3):e1101.
  533. Kumar P, Meena RN, Sheikh BH, Belliappa V, Pais AV. Intercostobrachial nerve — anatomical considerations and its importance in carcinoma breast of female patients. Ann Surg Perioper Care. 2016;1(2):1013.
  534. Mewa Kinoo S, Singh B. Complex regional pain syndrome of the breast and chest wall. Breast J. 2016;22(3):366 -8.
  535. Soares EW. Anatomical variations of the axilla. Springerplus. 2014;3:306.
  536. Zhu JJ, Liu XF, Zhang PL, Yang JZ, Wang J, Qin Y, Zhang GL, Ren DQ, Cui CL, Guo XG. Anatomical information for intercostobrachial nerve preservation in axillary lymph node dissection for breast cancer. Genet Mol Res. 2014;13(4):9315-23.
  537. Kim SC, Kim DW, Moadel RM, Kim CK, Chatterjee S, Shafir MK, Travis A, Machac J, Krynyckyi BR. Using the intraoperative handheld probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: a review of the literature. World J Surg Oncol. 2005;3:64.
  538. Dinas K, Kalder M, Zepiridis L, Mavromatidis G, Pratilas G. Axillary web syndrome: inci- dence, pathogenesis, and management. Curr Probl Cancer. 2019;43:100470.
  539. Koehler LA, Hunter DW, Blaes AH, Haddad TC. Function, shoulder motion, pain, and lymph- edema in breast cancer with and without axillary web syndrome: an 18-month follow-up. Phys Ther. 2018;98(6):518-27.
  540. Baggi F, Nevola Teixeira LF, Gandini S, et al. Axillary web syndrome assessment using a self- assessment questionnaire: a prospective cohort study. Support Care Cancer. 2018;26(8):2801 -7.
  541. Lauridsen MA, et al. The effect of physiotherapy on shoulder function in patients surgically treated for breast cancer: a randomised study. Acta Oncol. 2009;95:314-20.
  542. Wanga T, Xub D, Liao Z. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. J Curr Surg. 2018;8:32-4.
  543. Montgomery LL, Thorne AC, Van Zee KJ, et al. IB dye reactions during SLN mapping for breast cancer. Anesth Analg. 2002;95:385-8.
  544. MacNeill F. New start: the UK SLNB training programme, a progress report. Ann R Coll Surg Engl (Suppl). 2007;89:60-1.
  545. Wohrl S, Focke M, Hinterhuber G, Stingl G, Binder M. Near-fatal anaphylaxis to patent blue V. Br J Dermatol. 2004;150:1037-8.
  546. The Society of Hospital Epidemiology of America; The Association for Practitioners in Infection Control; the Centers for Disease Control; The Surgical Infection Society. Consensus paper on the surveillance of surgical wound infection. Infect Control Hosp Epidemiol. 1992;13:599-605.
  547. De Gournay E, et al. Impact of sentinel node biopsy on long-term quality of line in breast cancer patients. Br J Cancer. 2013;109:2783-91.
  548. Kuehn T, Klauss W, Darsow M, Regele S, Flock F, Maiterth C, Dahlbender R, Wendt I, Kreienberg R. Long-term morbidity following axillary dissection in breast cancer patients-clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat. 2000;64(3):275-86.
  549. Kissin MW, Querci della Rovere G, Easton D, Westbury G. Risk of lymphoedema following the treatment of breast cancer. Br J Surg. 1986;73(7):580-4.

- Вернуться в оглавление раздела "Стоматология"

Редактор: Искандер Милевски. Дата обновления публикации: 28.9.2026